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1 Introduction 
1.1 The skeletal muscle 
The major function of a skeletal muscle is to contract and by that to generate force for most of 
the essential processes in a living organism. The functional commitment of muscle tissue is 
extremely broad, ranging from the very complicated neuromuscular orchestration of walking, 
to the mechanistic execution of breathing and the highly fine tuned sensual process of seeing. 
But generating motion is not the only crucial duty of skeletal muscles. Skeletal muscles gen-
erate heat during contraction and amongst other functions, they safe the appropriate tempera-
ture homeostasis and thereby prevent the individual’s body hypothermia (sever under-
cooling). Even more important is the essential role of skeletal muscle tissue in energy alloca-
tion. Being the most abundant tissue in the human body (40 to 50 % of the total body mass in 
mammals, depending on gender, body height and fitness) the skeletal muscle is capable of 
releasing amino acids into the blood stream through intracellular catabolic processes. Thereby 
muscle mass degradation serves as a backup reservoir for various organs (including heart, 
brain and liver) in periods of fasting, during catabolic events or diseases, such as cancer, sep-
sis, AIDS and heart failure. The catabolic processes leading to skeletal muscle atrophy will be 
introduced in the following chapter in more detail. This study focuses on the identification of 
novel transcriptional regulators involved in degradation mechanisms leading to skeletal mus-
cle atrophy. (Fanzani, Conraads, Penna, & Martinet, 2012a; Gundersen, 2011) 
1.2 Skeletal muscle atrophy 
The skeletal muscles are highly plastic organs, their structure and functional unity is tightly 
regulated by a multiplicity of pathways. Under normal conditions the pathways crosstalk as-
sures a proper balance between protein synthesis and protein degradation and leads to a ho-
meostatic muscle composition. This balance is influenced by external stimuli such as physical 
activity, availability of nutrients and growth factors as well as mechanical stresses. During the 
process of skeletal muscle atrophy, which is defined by a reduction of cross-sectional area 
(CSA) of the muscle fiber diameter and an impaired strength in the skeletal muscle, the ubiq-
uitin related proteolytic systems are getting activated (Stewart H. Lecker, Solomon, Mitch, & 
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Goldberg, 1999; Tawa, Odessey, & Goldberg, 1997). The range of triggering events conduct-
ing to skeletal muscle atrophy is large. On the one hand, pathologic skeletal muscle atrophy 
can be provoked by external stimuli like immobilization (e.g. bed rest, fixation) or micro- to 
zero-gravity events (e.g. spaceflights) leading to severe and rapid degradation of contractile 
proteins and/or whole organelle structures. In contrast, more physiological triggers for skele-
tal muscle atrophy can be missing neuromuscular stimulation as caused by denervation or 
several neurological disorders as well as a series of systemic diseases (e.g. cancer, kidney 
diseases, heart failure, sepsis and infections as HIV/AIDS). (Bonaldo & Sandri, 2012a; Glass, 
2005; Sartorelli & Fulco, 2004; Y. Wang & Pessin, 2013)  
Additionally, the loss of muscle mass in the seniority, called sarcopenia, is a public health 
problem that can be a first cause of severe reduction in mobility and by that a reduction in an 
individual’s life quality (Thomas, 2007). An ongoing and severe loss of muscle mass is often 
associated with poor prognosis in diseases survival of suffering individuals, in case of myopa-
thies and muscular dystrophies, heart failure, chronic kidney disease (CKD), diabetes, sepsis 
and cancer. All these diseases share the chance of an end stage development of cachexia (def-
inition: weight loss >5% or >2% with a body-mass-index, BMI <20), which is characterized 
by weakness and weight loss, including loss of fat and muscle mass. Expectedly, cachexia is a 
complex metabolic syndrome that can strongly increase morbidity as well as mortality and 
lead to a severe reduction in life quality. (Amitani et al., 2013; Lainscak et al., 2008; Thomas, 
2007)  
In the complex process of cachexia pro-inflammatory cytokines such as angioten-
sin II (AngII), tumor necrosis factor-alpha (TNF-α), TNF-related weak inducer of apopto-
sis (TWEAK), interleukin-1 (IL-1) and interleukin-6 (IL-6) are suggested to be involved in 
the induction of muscle wasting by enhancing the activation of the proteolytic degradation 
machinery (Amitani, Asakawa, Amitani, & Inui, 2013; Lainscak, Filippatos, Gheorghiade, 
Fonarow, & Anker, 2008; Tadashi Yoshida et al., 2013a).  
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1.2.1 Molecular mechanisms and pathways involved in skeletal muscle 
atrophy 
In the past 20 years, the process and regulation of skeletal muscle atrophy has been drawn 
into focus by several scientific research groups. As pioneers in modern atrophy research, the 
laboratories of Alfred L. Goldberg and David J. Glass could independently identify the E3 
ubiquitin ligase named muscle specific RING (really interesting new gene) finger 1 (MuRF1 
or Trim63) and the F-box protein family member 32 (Fbxo32 or atrogin1/MAFbx). Expres-
sion of both MuRF1 and atrogin1 were highly increased in skeletal muscles of rats and mice 
upon immobilization, denervation or hind-limb suspension (a muscular disuse approach) in-
duced atrophy (Bodine, Latres, et al., 2001a; Gomes, Lecker, Jagoe, Navon, & Goldberg, 
2001a). In mice, gene deficiencies for either MuRF1 or atrogin1 lead to a strong reduction in 
denervation induced skeletal muscle weight loss and the reduction of muscle fiber diameter 
decrease (Bodine, Latres, et al., 2001a; Gomes et al., 2001a). During the following years, it 
has been proven that the expression of MuRF1 as well as atrogin1 is increased in various at-
rophy models (Bonaldo & Sandri, 2012a; Glass, 2005). Since then, both genes serve as atro-
phy markers and their specific regulating pathways where drawn into focus (Sandri, 2008).  
 
IGF-1/Insulin-PI3K-Akt-FoxO Pathway  
One of the best-characterized examples influencing muscle composition is the insulin-like 
growth factor 1 (IGF-1) triggered PI3K/Akt/FoxO signaling cascade. IGF-1 is involved in cell 
proliferation, differentiation, myofiber growth and regeneration (reviewed in Fanzani et al., 
2012). It activates the phosphatidylinositol 3-kinase (PI3K) - protein kinase B (PKB or AKT) 
pathway, which in turn blocks the Forkhead box (FoxO) transcription factor family activity 
(Sacheck, Ohtsuka, McLary, & Goldberg, 2004; Y.-H. Song et al., 2005; Stitt et al., 2004). 
The FoxO family of transcription factors has been reported to induce MuRF1 and atrogin1 
expression in different atrophy models (Reed, Sandesara, Senf, & Judge, 2011; Stitt et al., 
2004). In contrast, low circulating IGF-1 levels, which have been associated with sarcopenia, 
CHF, cancer (Costelli et al., 2006) and other syndromes, can be a triggering event that leads 
to loss of muscle mass (reviewed in Fanzani et al., 2012). In addition, IGF-1 treatment reduc-
es MuRF1 and atrogin1 mRNA expression in C2C12 myotubes (skeletal muscle mouse cell 
line) and blocks dexamethasone (Dexa) induced protein breakdown, probably by its strong 
negative influence on atrogin1 expression (atrogin1 mRNA expression at ~40% after 3h 
IGF-1 treatment) (Sacheck et al., 2004). The transcription factor FoxO1 binds to the MuRF1 
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promoter and increases its binding upon Dexa treatment (Waddell et al., 2008a). But it is of 
interest, that in-vivo gain of function approaches using FoxO3a could only show a ~2 fold 
increase of MuRF1 activation in a luciferase promoter assay (Senf, Dodd, & Judge, 2009). 
Furthermore, a constitutive active mutant of FoxO1 (caFoxO1), was not sufficient to induce 
MuRF1 mRNA expression in C2C12 myotubes (Stitt et al., 2004).  
In conclusion, the involvement of the FoxO transcription factor family in the regulation of 
muscle atrophy is significant and seems to be relevant for the induction of MuRF1 and 
atrogin1 in skeletal muscle atrophy and in the IGF-1 mediated inhibition of protein degrada-
tion. However, the FoxO transcription factor family seems to be more important for atrogin1 
than for MuRF1 regulation. These and other evidences led us to the assumption of the exist-
ence of other relevant transcription factors which could be involved in MuRF1 regulation and 
thereby mediate skeletal muscle atrophy.  
 
The NF-κB pathway  
The classical NF-κB pathway is involved in the cellular response to stress, cytokines, 
UV-light irradiation mediated DNA damage, bacterial and viral infections, as well as to oxi-
dative stress. The so called canonical NF-κB pathway can be triggered by TNF-α, TWEAK 
and IL-1β. The specific receptor stimulation of IL-1β activates and recruits different complex 
members (TAK1 complex) which in turn activate the central IκB kinase (IKK) complex 
(composed out of IKKα, IKKβ and the linking IKKγ subunit). The IKKβ kinase subunit 
marks the IκBα suppressor protein via phosphorylation, which in turn gets ubiquitinated and 
degraded in the proteasome. The unbound or de-suppressed transcription factor dimers (e.g. 
p50 and p65) translocate to the nucleus and activate gene transcription. (Gilmore, 2006; 
Jackman, Cornwell, Wu, & Kandarian, 2013; Perkins, 2007; Peterson, Bakkar, & Guttridge, 
2011) 
Being also expressed in skeletal muscle tissue, the activation of the NF-κB pathway has been 
reported in different states of atrophy/cachexia (Cai et al., 2004a; Hunter et al., 2002; Y.-P. Li 
& Reid, 2000; Penner, Gang, Wray, Fischer, & Hasselgren, 2001; Peterson et al., 2011). As 
mentioned before, the NF-κB cascade can be stimulated by TNF-α (Y.-P. Li & Reid, 2000), 
whose circulating levels were shown to be increased in patients suffering from cancer cachex-
ia (Argilés & López-Soriano, 1999; Tisdale, 1997).  
Supporting the involvement of NF-κB in systemic atrophy development, Ladner et al. showed 
that NF-κB is required for TNF-α induced atrophy by using an IκBα super-repressor (SR; 
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non-degradable form of IκBα) C2C12 cell line (Ladner, Caligiuri, & Guttridge, 2003). In the 
following year Cai et al. (Cai et al., 2004a) used a muscle-specific transgenic mouse line 
over-expressing an active form of IκB kinase β (called MIKK), which showed significant 
muscle wasting even without atrophying stimulus. In addition, a very interesting and im-
portant result of this study was that the NF-κB mediated muscle wasting affected only the 
expression of MuRF1, but showed no effect on atrogin1 expression. MuRF1 mRNA expres-
sion moderately increased in tibialis anterior (TA) muscles of MIKK mice (~3 fold) and 
MuRF1 promoter fragments showed very low response to the NF-κB mediated signals in dif-
ferent luciferase assay approaches (Cai et al., 2004a). This means that in summary, the NF-κB 
pathway plays a central role for regulation and progression of skeletal muscle atrophy. Sever-
al loss-of-function approaches showed that the NF-κB pathway is crucial for denervation and 
immobilization induced atrophy. But gain-of-function approaches showed only little, if any, 
positive regulatory effects on MuRF1 and atrogin1 expression. Therefore, the induction of 
MuRF1 and atrogin1 observed in most of the skeletal muscle atrophy models cannot be com-
pletely explained by involvement of only one pathway. 
 
The mTOR pathway, downstream of Akt 
The “original” target of rapamycin (TOR) pathway components where first identified in yeast 
(Crespo & Hall, 2002). Major cellular processes regulated by the mammalian target of ra-
pamycin complex 1 (mTORC1) are protein and lipid synthesis, lysosomal biogenesis, energy 
metabolism and autophagy (Hay & Sonenberg, 2004; Mathieu Laplante & Sabatini, 2012; 
Wullschleger, Loewith, & Hall, 2006). The mTOR pathway has been linked to a variety of 
diseases like atrophy, several cancers, obesity and type 2 diabetes (Bentzinger et al., 2013; 
Bodine, Stitt, et al., 2001). In more detail, the mTORC1 pathway integrates intra- and extra-
cellular stimuli like growth factors and nutrient supplementation; moreover it participates in 
energy status regulation and senses other stress factors. The catalytic active protein of mTOR, 
a serine threonine kinase belonging to the phosphoinoside-3-kinase related (PI3K) family, 
interacts with several other proteins forming two different complexes, named mTOR com-
plex 1 (mTORC1) and mTOR complex 2 (mTORC2). The better characterized mTORC1 is 
more sensitive to rapamycin inhibition, as it interacts directly with the “gain-of-function” 
complex formed from rapamycin and the FKBP12 protein (Brown et al., 1994; Mathieu La-
plante & Sabatini, 2012; Sabatini, Erdjument-Bromage, Lui, Tempst, & Snyder, 1994).  
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The second mTOR complex (mTORC2) shows inhibition effects only after long term treat-
ment and independent of FKBP12/rapamycin complex binding (Dos D. Sarbassov et al., 
2004; Sarbassov et al., 2006). When active, mTORC2 is involved in regulation of cell surviv-
al, metabolism and cytoskeleton organization (M. Laplante & Sabatini, 2013; Mathieu 
Laplante & Sabatini, 2012).  
In 2008 Bentzinger et al. showed that skeletal muscle specific ablation of the mTORC1 com-
plex protein raptor (regulatory-associated protein of mTOR) resulted in smaller muscles and 
led to muscle dystrophy and a soon death shortly after birth (Bentzinger et al., 2008). Earlier 
studies presented evidences towards an involvement of the mTORC1 pathway in muscle size 
control (Rommel et al., 2001). Wan et al. were able to show that indirect inhibition of 
mTORC1 via transgenic overexpression of TSC1, which forms an upstream inhibitory com-
plex with TSC2, resulted in muscle atrophy (Wan et al., 2006). In addition, a recent study of 
Bentzinger et al. (Bentzinger et al., 2013) underlined these previous results by analyzing 
TSC1-deficient mice in reference to hypertrophy and atrophy signaling events. The investiga-
tors could indicate that ongoing activation of the mTORC1 pathway by genetic deletion of the 
inhibitory Tsc1 gene induced atrophy in all but the soleus muscle. Their biochemical analysis 
pointed out to a PKB/Akt mediated inhibitory feedback mechanism by mTORC1 that led to a 
subsequent induction of MuRF1 and atrogin1 (Bentzinger et al., 2013). The suggested cross-
talk between Akt-FoxO and the mTORC1 pathway, which is important for lysosomal for-
mation and autophagosomal biogenesis (Sardiello et al., 2009; Settembre et al., 2012), is sup-
ported by the findings of two independent groups in 2007. These groups showed that FoxO3 
induces major lysosomal and autophagosomal genes as well as atrogin1 (Mammucari et al., 
2007; Zhao et al., 2007a). However, it has to be mentioned that in the same study of Zhao et 
al. rapamycin mediated mTOR inhibition faintly (~10%) increased protein breakdown in my-
otubes (Sandri, 2010). Given that, mTORC participates in skeletal muscle atrophy develop-
ment, but was shown to be not the primarily responsible pathway.  
 
The AMP-activated protein kinase (AMPK) 
Serving as a general sensor for cellular energy balance, the 5’-adenosine monophosphate-
activated protein kinase (AMPK) plays a central role in the skeletal muscle tissue as a key 
regulator of the oxidative capacity, cell growth and balances metabolic gene expression 
(Bonaldo & Sandri, 2012a; Sean L. McGee & Hargreaves, 2010).  
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Due to its critical participation in energy pathway regulation, it was taken into focus of the 
atrophy research field. Thus, in 2007 two independent groups could show that AMPK activa-
tion led to FoxO3 phosphorylation independent of the previously mentioned Akt pathway 
phosphorylation of FoxO3 (Greer, Dowlatshahi, et al., 2007; Greer, Oskoui, et al., 2007; 
Nakashima & Yakabe, 2007). The chemical activation of AMPK, using the adenosine ana-
logue AICAR (5-Aminoimidazole-4-carboxamide ribonucleotide) led to an increase in protein 
degradation, but showed little effect on MuRF1 and atrogin-1 expression (Nakashima & 
Yakabe, 2007). In 2012, an adjacently published study showed the same moderate effect of 
AICAR on the MuRF1 (~1.5 fold) and atrogin-1 (~1.9 fold) expression in primary myotubes 
and assigned major parts of the observed protein degradation to the induction and transcrip-
tional activation of autophagic components (e.g. LC3) and the autophagosomal formation in 
skeletal muscle cells (Sanchez et al., 2012). AMPK shares a connective point with the mTOR 
pathway, where it can inhibit mTORC1 activity via phosphorylation of the TSC2 complex 
(Langen, Gosker, Remels, & Schols, 2013).  
A recent paper which investigated the regulating effect of AMPK on both atrogenes in the 
rodent heart showed in vivo data, which again indicated a faint mRNA expression increase of 
MuRF1 and atrogin-1 (~2.3 fold for both atrogenes) in AICAR treated NRVM cells (neonatal 
rat ventricular cardiomyocytes). The authors addressed the MuRF1 induction to the myocyte 
enhancer factor 2 (MEF2) (Baskin & Taegtmeyer, 2011a). The MEF2 family of transcription 
factors is composed of four members A, B, C and D; they are central regulators of develop-
mental processes, amongst other in skeletal muscle tissue (M. J. Potthoff & Olson, 2007). 
Focusing on muscle atrophy and the regulation of MuRF1, it is of interest that the MuRF1 
promoter from human as well as other mammalian species shows a highly conserved MEF2 
binding site in nearest proximity to the transcriptional start of the MuRF1 gene (Andrés, Cer-
vera, & Mahdavi, 1995; Baskin & Taegtmeyer, 2011a). Baskin et al. showed that mutation of 
the MEF2 binding site led to reduced induction by AICAR in H9C2 cells (mouse heart) in a 
luciferase assay system. Nutrient deprivation and active isoforms of AMPK, as well as its 
regulatory effects on MuRF1 expression in connection with skeletal muscle atrophy develop-
ment have not been investigated so far. It is important to note, that several publications have 
shown a strong regulatory connection between MEF2 and ClassIIa histone-deacetylases 
(HDACs), which have been proven to be negative regulators of skeletal muscle atrophy 
(Miska et al., 1999; Matthew J. Potthoff et al., 2007). The role and function of ClassIIa 
HDACs in muscle atrophy will be elucidated in a following specialized chapter.  
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The transcription factor myogenin 
An important regulator of atrogene gene expression in denervation induced atrophy is the 
bHLH transcription factor myogenin (Macpherson, Wang, & Goldman, 2011; Viviana Moresi 
et al., 2010a; Tiffin, Adi, Stokoe, Wu, & Rosenthal, 2004). Myogenin is essential for skeletal 
muscle development, since mice with partial germ line deletion of the myogenin gene died 
immediately after birth and showed skeletal defects (Hasty et al., 1993; Nabeshima et al., 
1993). Due to these findings, Moresi et al. used an inducible knockout strategy to investigate 
the role of myogenin in denervation induced atrophy (Viviana Moresi et al., 2010a). Moresi et 
al. showed that myogenin binds to conserved E-box sequences (CANNTG, Figure 2) in the 
MuRF1 promoter and that overexpression of myogenin induced MuRF1 (~10 fold) and 
atrogin-1 (~3 fold) promoter constructs in C2C12 myoblasts in an E-box dependent manner. 
Myogenin deficient mice showed reduced MuRF1 and atrogin-1 mRNA induction upon de-
nervation, but no effect after 48 h of fasting (Moresi et al., 2010). Supporting evidences from 
the lab of Daniel Goldman showed a reduced effect on denervation mediated reduction of 
muscle atrophy, at least for the soleus muscle (Macpherson et al., 2011). 
Furthermore, Moresi et al. in 2010 as well as Bricceno et al. in 2012 showed that class IIa 
histone deacetylases (HDAC) 4 and 5 are both regulators of skeletal muscle atrophy, and that 
this process involves myogenin mediated atrogene induction (Bricceno et al., 2012; Viviana 
Moresi et al., 2010b).  
The chemical blockade or genetic deactivation of individual pathway components has been 
shown to be able to block atrophy in denervation induced atrophy. This recently discovered 
connection of myogenin to denervation induced atrophy and the negative regulation of class 
IIa HDAC4 and 5 in that process added in a new optional pathway that influences MuRF1 and 
atrogin-1. 
Summing up these findings, the understanding of the crosstalk between signaling pathways 
participating in skeletal muscle maintenance widens up, but the complicated orchestration of 
various stimuli influencing the skeletal muscle structure and development of atrophy is not 
fully understood.  
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Figure 1: Regulators of MuRF1 expression 
The diagram summarizes atrophy stimuli and their influences via indicated regulators on MuRF1 expression. 
Transcription factor families as well as class IIa histone deacetylases (HDAC) being involved in MuRF1 regula-
tion are indicated. Nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB); myogenin (Myog); 
Forkhead box binding transcription factor (FoxO); Myocyte enhancer factor 2 (Mef2); interrogation mark repre-
sents unknown regulators supposedly being involved in MuRF1 regulation.   
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Figure 2: Transcription factor binding sites within the MuRF1 promoter structure  
The diagram shows an illustration of the human MuRF1 promoter region, representing 1000 base pairs (bp) 
upstream of the transcriptional start site (Gene ID: 84676). Transcription factor families involved in MuRF1 
regulation are indicated. Myocyte enhancer factor 2 (Mef2); myogenin (Myog); Forkhead box binding transcrip-
tion factor (FoxO); nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB); subtitled publica-
tions indicate investigators of regulatory mechanisms. Binding sites for MEF2, E-Box positions 1 to 5, F-Box 
site; glucocorticoid response element (GRE) and the NF-κB sites are shown relatively to their indicated distance 
to human MuRF1 transcription start. Lower panel shows sequence alignment of indicated species, with stars 
representing sequence coincidence and dotted lines for aberrations. GRE and Fbox site overlap at one position; 
both sequence elements are marked with corresponding colored boxes. 
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1.3 Protein degradation in cell biology  
The two major mechanisms for protein degradation in eukaryotic cells are the ubiquitin-
proteasome system (UPS) and the autophagy - lysosome pathway (Fanzani, Conraads, Penna, 
& Martinet, 2012; Sandri, 2013). In general and under normal conditions the UPS is mainly 
involved and responsible for the targeted degradation of short lived proteins, whereas the au-
tophagic machinery degrades long lived proteins and whole organelle structures (Fanzani et 
al., 2012a). During the advance and acute state of skeletal muscle atrophy both degradational 
mechanisms have been reported to be activated and to differentially contribute to loss of mus-
cle proteins (reviewed in Bonaldo and Sandri, 2012b; Fanzani et al., 2012; Schiaffino et al., 
2013). 
1.3.1 The ubiquitin-proteasome system  
The muscle tissue includes a strong requirement for specific and profoundly regulated degra-
dation of target proteins or selective subsets of proteins, e.g. as a process adaptation to differ-
ent conditions in activity and maintenance. This target-oriented and precisely orchestrated 
protein disassembly is mainly performed by the UPS via a highly selective and target specific 
transfer of multiple ubiquitin peptide residues (76 amino-acids, 8 kDa) as marking signals for 
a subsequent degradation in the proteasome. Ubiquitin is expressed in all eukaryotic cell types 
and its sequence is conserved from yeast to human. To achieve highest specificity, the UPS is 
composed gradually of target recognizing enzymes at its cascade end. (S. H. Lecker, 2006) 
The first process-related steps include an ATP consuming activation and binding of one ubiq-
uitin (Ub) residue to the E1 ubiquitin-activating enzyme and the subsequent transfer of this 
Ub monomer to an E2 ubiquitin-conjugating enzyme. Successively, the Ub carrying E2 en-
zyme then binds to the specificity mediating E3 ubiquitin ligase. The intrinsic ubiquitin-
marking procedure, which covalently binds the ubiquitin molecule to a lysine residue of the 
target protein, can be mediated directly by the E3 ligase, which transfers the ubiquitin on the 
target protein. The E3 ligase can also serve as a linker for an indirect E2 enzyme mediated 
labeling. Repeated elongation of the ubiquitin chains to at least four ubiquitin residues, linked 
via lysine 48, demonstrate the “classical” recognition signal for subsequent degradation in the 
proteasome. All seven lysine residues within the ubiquitin protein can serve as potential con-
jugating sites and lead to different types of chains (Lys 6, 11, 27, 29, 33, 48 and 63). Some 
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ubiquitylation positions function as regulatory modifications, while others lead to degrada-
tion. (Glickman & Ciechanover, 2002; Stewart H. Lecker, 2003; Pickart, 2000; Weissman, 
2001; Wilkinson, 2000) 
The human genome encodes for more than 650 different ubiquitin ligases. These E3 ligases 
are involved in the regulation of metabolism, cell cycle, transcription and muscle mass con-
trol. Considering a tissue specific expression of E2s and E3s, different E2-E3 pairs degrade 
different proteins and by that enhance the preciseness of the UPS (Bonaldo & Sandri, 2012b). 
It is necessary to mention, that the transfer of single ubiquitin residues (mono-ubiquitylation) 
can have different effects concerning the targeted protein and influence e.g. its function or its 
sub-cellular localization. Besides that, ubiquitin residues can be removed by de-ubiquitinating 
enzymes (DUBs), which negatively regulate the effect of the ubiquitin cascade (Glickman & 
Ciechanover, 2002).  
Summing up, the specified mechanism of targeted degradation of muscle proteins via the UPS 
is arranged by the interplay of ubiquitin activating (E1), conjugating (E2) and transferring or 
ligating enzymes (E3), but the 26S proteasome complex performs the ultimate proteolytic 
degradation process. 
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Figure 3: The ubiquitylation cascade 
This schematic illustration shows the process of ubiquitylation and the connected mechanisms. Ubiquitin (Ub) 
gets activated by the E1 enzyme via using ATP hydrolyzing energy, Ub is then passed to an E2 Ub-conjugating-
enzyme. The Ub is adjacently transferred to a target or substrate protein, this process is supported by a target 
specific E3 ligase. RING (really interesting new gene) E3 ligases act as scaffold proteins, which pass the Ub 
from the E2 to the substrate protein. More Ub residues can be added via repeated “normal” ubiquitylation or by 
covalent coupling of pre-assembled polyUb chains from an E4 ligase (not illustrated). Covalently bound Ub 
residues can be cleaved off the substrate protein at any point in the process by de-ubiquitylating enzymes 
(DUBs). Graphical information and layout have been adapted from McDowell and Philpott 2013 and Bonaldo 
and Sandri 2012.   
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1.3.2 The proteasome 
The proteasomal degradation is a stepwise mechanism with distinct and specialized functions 
for each section of the proteasome complex. It consists of two general subunits: a central core 
structure with hydrolysis activity called the core particle (CP) or 20S proteasome and the reg-
ulatory particle (RP) or 19S particle subunit. The RP is the substrate recognition subunit and 
responsible for the ATP-dependent unfolding of the target protein, removal of the ubiquitin 
chain and the subsequent translocation into the CP. In a progressive mechanism, the linear-
ized protein enters the CP and gets degraded into peptide fragments. (Finley, 2009; Schmidt 
& Finley, 2013)  
The CP is assembled out of 28-subunits; two alpha-rings are covered at both sides with two 
beta-rings forming together a barrel like core, which catalyzes the peptide bond cleavage at 
the end of the proteolytic process. The RP complex can bind to either side of the CP and con-
tains 10 subunits forming a base and a lid sub-complex, whereas the base includes six 
ATPases, which utilize ATP energy for the unfolding process. On the other hand, the lid part 
is suggested to recognize and de-ubiquitinylate the target proteins. The molecular architecture 
of the 26S proteasome complex can be reviewed in Nickell et al. (2009). 
The proteasome is the final executing part of the UPS. The involvement of the UPS in skeletal 
muscle atrophy and many other diseases has been reported by others (Murton, Constantin, & 
Greenhaff, 2008; Pagan, Seto, Pagano, & Cittadini, 2013; Petroski, 2008; Schmidt & Finley, 
2013; Sohns, van Veen, & van der Heyden, 2010).  
By the matter of fact, the specificity of degradation is mediated by the E3 ligases of the ubiq-
uitin system. This marking section moved into focus of research as potential interfering point 
for the prevention of diseases and drug development. 
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1.3.3 The autophagy-lysosome system  
Autophagy is a central part of the cells recycling and turnover system. The autophagy-
lysosome system digests whole cell components, long-lived proteins and vesicular proteins 
via fusion of the vesicles with lysosomes. Autophagic dysfunction has been associated with 
skeletal muscle atrophy in humans and other diseases like cancer, microbial infections, neu-
ron-degeneration, myopathies and heart disease. (Bonaldo & Sandri, 2012b; Mizushima, Lev-
ine, Cuervo, & Klionsky, 2008) 
Core machinery of the autophagy process is the lysosome, a vesicular structure present in 
mammalian cells with an acidic pH of 4-5, raised by ATP-consuming proton pumps. Lyso-
somes import proteases, lipases, nucleases, phosphatases, hydrolases and glycosidases via the 
endoplasmic reticulum and the Golgi apparatus; all together execute the digestion process. In 
general, the lysosomal degradation is fed by three different substrate-delivering mechanisms: 
the micro-autophagy, the macro-autophagy and the chaperone-mediated autophagy (CMA). In 
addition, extracellular proteins and other substances can be digested in the lysosome as well 
via endocytotic internalization and vesicle fusion. Small portions of cytoplasm can directly be 
transferred into the lysosome via invagination of its membrane, representing the micro-
autophagy. This mechanism has not been described in skeletal muscle cells so far. In the 
CMA degradation process the cytoplasmic target protein gets recognized by heat-shock pro-
tein hsc73 via sequence recognition of the amino acid motive Lys-Phe-Glu-Arg-Gln and 
bound to the lysosomal membrane via the receptor protein LAMP2. During macro-autophagy 
big protein complexes and whole cytoplasmic organelles get surrounded by a double mem-
brane vesicle generating the autophagosome. Beforehand, the formation of the so called pre-
autophagosomal structure, assisted by several multi-complex associated proteins, is necessary 
before fusion with the lysosome and subsequent target degradation. Macro-autophagy has 
been observed and investigated in skeletal muscle tissue and seems to be very relevant for the 
healthy maintenance of skeletal myofibers. Various myopathies and dystrophies have been 
linked to an impairment of lysosomal function or autophagy dysfunction due to mutations in 
different lysosomal/autophagosomal genes including chloroquine induced myopathy, Pompe 
disease, Danon disease, Bethlem myopathy and Ullrich congenital muscular dystrophy. 
(Bechet, Tassa, Taillandier, Combaret, & Attaix, 2005; Bonaldo & Sandri, 2012b; Mizushima 
et al., 2008) 
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1.4 The E3 ubiquitin ligase MuRF1 and the F-box protein atrogin1 
The dual discovery of the muscle-specific E3 ubiquitin ligases MuRF1 (or Trim63) and the 
muscle-specific F-box protein atrogin1 (or MAFbx), following transcript profiling of rodent 
fasting and immobilization atrophy models, raised great expectations in the development of 
new therapeutics for a more specified treatment of skeletal muscle atrophy events (Bodine, 
Latres, et al., 2001b; Gomes, Lecker, Jagoe, Navon, & Goldberg, 2001b). During the follow-
ing years after discovery their importance in skeletal muscle atrophy strengthened by func-
tional characterization and identification of individual target proteins. On the one hand, both 
gene expressions where observed to be increased in various models of skeletal muscle atrophy 
including cancer, rheumatoid cachexia, diabetes, denervation, renal failure and glucocorticoid 
or cytokine treatment. On the other hand, rodent knockout models showed resistance to de-
nervation induced muscle atrophy for both proteins (Bodine, Latres, et al., 2001b). (Foletta, 
White, Larsen, Léger, & Russell, 2011)  
Continuing molecular characterizations highlighted completely different targets for both pro-
teins. For atrogin1, only a few targets were identified as substrates for degradation. In addi-
tion to myogenic differentiation 1 (MyoD), which is a key transcription factor in muscle dif-
ferentiation (Tintignac et al., 2005), it arranges degradation of eukaryotic translation initiation 
factor 3 subunit F (eIF3f), an activator of protein synthesis (Csibi et al., 2010). In the heart 
atrogin1 reduces calcineurin A levels, which is an important factor in response to pressure 
overload induced hypertrophy (H.-H. Li et al., 2004).  
In contrast, the E3 ubiquitin ligase MuRF1 mediates degradation of proteins associated within 
the sarcomere. Early in-vitro studies in the lab of Siegfried Labeit showed that MuRF1 binds 
to the giant myofibrillar protein titin and is assumed to have regulatory influence on titans’ 
kinase activity (Centner et al., 2001). MuRF1 also regulates stability of troponin I, myosin 
heavy chain proteins (Clarke et al., 2007a; Fielitz, Kim, et al., 2007; Kedar et al., 2004a), my-
osin binding protein C and myosin light chain (Cohen et al., 2009). All together, the degrada-
tional targets so far known for atrogin1 seem to be more growth, synthesis and survival asso-
ciated. However, the targets of MuRF1 are functional relevant for the muscle maintenance 
(Bonaldo & Sandri, 2012b). These findings implicate a separate functional involvement of 
MuRF1 and atrogin1 in skeletal muscle atrophy. Considering the differences in target ar-
rangement, the study was aimed to the identification of factors regulating MuRF1 expression.  
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1.4.1 Involvement of angiotensin II in skeletal muscle atrophy 
The renin-angiotensin system (RAS) is a hormone system regulating blood pressure, water 
balance and cardiac hypertrophy. The process involves multiple conversions of the liver se-
creted angiotensinogen propeptide to angiotensin I (AngI), catalyzed by renin, which is se-
creted from the kidney. Finally, AngI is converted by the angiotensin-converting enzyme 
(ACE) into fully active angiotensin II (AngII) which influences a multiplicity of body func-
tions. AngII activates multiple pathways, which regulate muscle mass, and has been linked to 
muscle wasting. (Tadashi Yoshida et al., 2013b) 
Individuals suffering from CHF, CKD or myocardial infarction have increased AngII levels 
(Anker et al., 2003; Jin et al., 2004; Roig et al., 2000). AngII treatment in rats leads to a loss 
of body weight by increased proteolysis in skeletal muscle and reduced food intake (M Brink, 
Wellen, & Delafontaine, 1996). Brink et al. showed in rats that AngII induced protein degra-
dation in muscle tissue was mainly mediated by the UPS (Marijke Brink et al., 2001). 
Expression levels for MuRF1 and atrogin1 have been shown to be elevated in AngII-induced 
muscle wasting (Semprun-Prieto et al., 2011; Y.-H. Song et al., 2005; T. Yoshida, Semprun-
Prieto, Sukhanov, & Delafontaine, 2010a). Surprisingly, activation of the IGF-1/Akt/FoxO 
pathway only abolished AngII induced atrogin1 but not MuRF1 expression (T. Yoshida et al., 
2010a). These results show that FoxO transcription factors are not responsible for MuRF1 
regulation in AngII induced atrophy.  
1 Introduction 28 
1.5 The transcription factor EB - TFEB 
The basic helix-loop-helix (bHLH) leucine zipper (LZ) domain containing transcription factor 
EB (TFEB) was first identified in a cDNA screen (Carr & Sharp, 1990). Shortly after, Fisher 
et al. confirmed the DNA binding ability of TFEBs bHLH domain and additionally identified 
the leucine zipper (LZ) domain as essential for homo- or heterodimerization with other tran-
scription factors, e.g. its family member TFE3 (Fisher, Carr, Parent, & Sharp, 1991).  
TFEB is one of four family members of the micropthalmia-related family of transcription fac-
tors (MiTF/TFE), including MiTF, TFEB, TFE3 and TFEC (Figure 4). The different family 
members show tissue specific expressional and alternative splicing patterns (Kuiper, 
Schepens, Thijssen, Schoenmakers, & van Kessel, 2004), high structural homology in their 
family spanning and family characteristic activation domain (AD), bHLH and LZ domains 
(Haq & Fisher, 2011). Kuiper et al. showed that human TFEB is expressed in skeletal and 
heart muscle tissue and that is alternatively spliced at its 5’- end. Since, the resulting different 
splicing products did not show any in-frame start codon, the final gene product was supposed 
to be unaffected (Kuiper et al., 2004). 
 
Figure 4: Illustration of human micropthalmia transcription factor (MiTF/Tfe) family members 
Schematic illustration of human TFEB, MiTF, TFE3 and TFEC with conserved domain structures: activation 
domain (AD), basic helix-loop-helix domain (bHLH), leucine-zipper domain (LZ) and DUF3371 domain. 
Shown are the longest isoforms of TFEB, MiTF, TFE3 and TFEC with number of amino acids and accession 
numbers labeled at the right side. Positions of domains are shown relative to sequence length, position and size. 
The MiTF/TFE family regulates cell growth, differentiation and survival. Genetic deletions, 
including targeted knockouts, show severe developmental aberrations. More specifically, 
TFEB plays an essential role for placental vascularization in mice (Steingrímsson, Tessarollo, 
Reid, Jenkins, & Copeland, 1998). MiTF also participates in the eye development in dro-
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sophila (Hallsson et al., 2004). Mutations within genes of family members have been reported 
in connection with a variety of different cancers, e.g. MiTF in connection with melanoma 
cancers (Steingrímsson, Copeland, & Jenkins, 2004), TFE3 and TFEB can provoke renal cell 
carcinomas (Camparo et al., 2008), and TFE3 additionally accounts for alveolar soft part car-
cinomas (Steingrímsson et al., 2004). A genomic fusion of alpha (locus neighbor) to TFEB 
was found and described in renal tumors (Davis et al., 2003). (Haq & Fisher, 2011) 
Most importantly, TFEB was linked to the lysosomal biogenesis and the regulation of autoph-
agosomal formation in different tissues and cell types, such as bone and heart tissue (Ferron et 
al., 2013; Ma, Godar, Liu, & Diwan, 2012; Palmieri et al., 2011; Sardiello et al., 2009a; Set-
tembre et al., 2012a). These findings, and the results of this study, highlight a central regulato-
ry position for TFEB in the cells degradational processes. 
1.6 The histone-deacetylase family  
The histone deacetylases (HDAC) are a family of post-translational modifying enzymes, 
which can deacetylate histone and non-histone proteins. In general, the acetylation process of 
histone proteins releases them from DNA and enables transcriptional activation of target 
genes. HDACs regulate the basal composition of muscle tissue and mediate stimuli dependent 
changes in gene expression, which can lead to increased proteolysis in skeletal muscle or 
heart depending on the participating sub-class of HDACs (Viviana Moresi et al., 2010a; Rick 
B. Vega et al., 2004). The mammalian HDAC family is divided into four different (sub)-
classes. Class I HDACs (HDAC1, 2, 3 and 8) are widely expressed in different tissues and 
were associated with regulation of skeletal muscle homeostasis (V. Moresi et al., 2012). 
Class II HDACs are separated into two sub-classes, including class IIa HDACs (HDAC4, 5, 7 
and 9; Figure 5), mainly expressed in muscle tissues, and class IIb HDACs (HDAC6 and 10). 
(Alamdari, Aversa, Castillero, & Hasselgren, 2013; Kee & Kook, 2011; S. L. McGee & Har-
greaves, 2010; Timothy A. McKinsey, Zhang, & Olson, 2001)   
As shown by Moresi et al. (2010), class IIa HDAC4 and 5 function as negative-regulators of 
MuRF1 and atrogin1 during denervation induced atrophy using knockout mice, working via 
an inhibitory cascade finally regulating myogenin expression (Bricceno et al., 2012; Viviana 
Moresi et al., 2010a). HDAC4 was first identified and characterized by Miska et al. in 1999. 
In the same study the interaction and functional repression of MEF2A was published, which 
is one of the MuRF1 regulating transcription factors. The knowledge of this connection has 
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been expanded by several researchers, especially in the lab of Eric N. Olson, who added in the 
findings of a 14-3-3 dependent nuclear export not only of HDAC4, but also HDAC5, includ-
ing an upstream signaling cascade of the stress dependent serine/threonine kinase protein ki-
nase D1 (PKD1) (Fielitz et al., 2008; Kim et al., 2008; Martin, Kettmann, & Dequiedt, 2007; 
T. A. McKinsey, Zhang, & Olson, 2001; R. B. Vega et al., 2004).  
 
 
Figure 5: Illustration of the human ClassIIa Histone-Deacetylase (HDAC) family members 
Schematic illustration of HDAC4, HDAC5, HDAC7 and HDAC9, showing the longest isoform for each protein, 
with total amino acid residues and database accession number at the right side. The CtBP, MEF2 and HP1-
binding regions are illustrated in colored boxes together with the NLS and NES sites. CtBP: C-terminal-binding 
protein; HP1: heterochromatin P1; NLS: nuclear localization signal; NES: nuclear export signal. Positions and 
total length (AA; amino acids) are shown relative to sequence and element size, graphical information and layout 
where partially adopted from Martin et al. 2007 and Zhang et al. 2002.  
1.7 Protein kinase D family   
The protein kinase D (PKD) family of serine/threonine kinases includes three isoform mem-
bers: PKD1 (Valverde, Sinnett-Smith, Van Lint, & Rozengurt, 1994), PKD2 (Sturany, 2000) 
and PKD3 (Hayashi, Seki, Hattori, Kozuma, & Saito, 1999). The family members share struc-
tural characteristics as the catalytic domain (kinase domain), the pleckstrin homology (PH-
domain) domain and two N-terminal cysteine-rich domains (C1a and b-domain) (Fielitz et al., 
2008; LaValle et al., 2010; Rybin, Guo, Harleton, Zhang, & Steinberg, 2012; Q. J. Wang, 
2006). PKD proteins are involved in the regulation of a multiplicity of cellular functions like 
protection from oxidative stress, regulation of cell shape, proliferation, motility, adhesion, 
cancer and, most of interest, in gene transcript regulation (Eiseler et al., 2009; Fu & Rubin, 
2011; Karam, Legay, Auclair, & Ricort, 2012; LaValle et al., 2010). (Fu & Rubin, 2011) 
Several publications analyzed the regulatory mechanisms controlling PKD activation, demon-
strating a direct phosphorylation of at least two conserved serine residues by different PKC 
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isoforms, which in turn get activated by different triggering stimuli over G-protein coupled 
receptors (Tan, Xu, Ohba, Ogawa, & Cui, 2003; Q. J. Wang, 2006; Yuan, Bae, Cantrell, Nel, 
& Rozengurt, 2002; Zugaza, Sinnett-Smith, Van Lint, & Rozengurt, 1996).  
One of the well investigated regulatory mechanisms, influencing gene expression in the heart 
as well as skeletal muscle is the PKD1 – ClassIIa histone deacetylases (HDAC) – MEF2 axis. 
This axis has influence on the endurance and maintenance status of muscle tissue. As de-
scribed in special HDAC chapter, the ClassIIa family of HDACs coordinately represses gene 
expression with cell-type-specific functions. When activated by an external stimulus (e.g. 
endothelin-1 or angiotensin II) over PKC signaling, PKD1 translocates into the nucleus and 
phosphorylates HDAC5, which binds to 14-3-3 nuclear export proteins and gets exported 
from the nucleus and gene transcription can be enabled by MEF2 and other suppressed tran-
scription factors. (Fielitz et al., 2008; rev. Fu and Rubin, 2011; Kim et al., 2008; Vega et al., 
2004)  
Investigating muscle atrophy, it is of interest that the conflictive hypertrophic phenotype is 
strongly reduced in cardiac specific PKD1 knockout mice upon pressure overload or angio-
tensin II treatment, implying a central role of the PKD1-HDAC5 axis in muscle tissue protec-
tion and maintenance (Fielitz et al., 2008).  
Considering these frame conditions, class IIa HDAC repression as well as the positive PKD 
family regulatory aspect was included in this study and their influences on the newly identi-
fied MuRF1 inducing transcription factor was analyzed.  
 
Figure 6: Illustration of human protein kinase D (PKD) family members 
Schematic illustration shows domain organization of human protein kinase D family. PKD1, PKD2 and PKD3 
show highly homologue and species conserved C1a and C1b sites (red), pleckstrin homology domain (PH; 
green) and kinase domains (kinase; blue). The number of amino acids according to illustrated accession numbers 
for the individual PKD isoforms is shown on the right. Positions of domains are shown relatively to sequence 
length. 
  
1 Introduction 32 
Table 1: Knockout mouse phenotypes of skeletal muscle atrophy involved genes 
Gene Mouse model Phenotype Reference 
atrogin-1 KO no abnormal baseline phenotype 
protection from denervation-
induced atrophy   
Bodine et al. 2001 
MuRF1 KO no abnormal baseline phenotype 
protection from denervation-
induced atrophy   
Bodine et al. 2001 





Moresi et al.2010 
HDAC5 KO protection from denervation-
induced atrophy 





Moresi et al.2010 
PKD1 Cardiac-
specific KO 
diminished cardiac hypertrophy 
upon TAC, AngII and Isoproterenol 
Fielitz et al. 2007 
Myogenin Inducible KO protection from denervation-
induced atrophy 




muscle atrophy Kamei et al. 2004 
FoxO1 Muscle-
specific KO 
myofiber switch from slow to fast 
twitch fibers 
Kitamura et al. 2007 
FoxO3 Inducible KO no abnormal phenotype Paik et al. 2007 
MEF2A KO mitochondrial defects, sudden 
death after birth and cardiac defi-
ciencies  
Naya et al. 2002 
MEF2C Muscle-
specific KO 
disorganized myofibers and perina-
tal lethality 
Potthoff et al. 2007 
MEF2D Muscle-
specific KO 
reduction of slow fibers in the so-
leus muscle 
Potthoff et al. 2007 
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1.8 Aim of the study 
Skeletal muscle atrophy is a severe problem for individuals suffering from this disease and 
can occur as a result of a variety of different causes like cancer, sepsis, diabetes, AIDS as well 
as renal and heart failure. The diversity of triggering events and stimuli show the complex 
orchestration of skeletal muscle maintenance and point out to the participation of several par-
allel pathways working together in the regulation of skeletal muscle structure and the devel-
opment of muscle atrophy. Many questions concerning the regulation of muscle atrophy are 
still unanswered. The skeletal muscle specific E3 ubiquitin ligase MuRF1 has been described 
to be important in skeletal and heart muscle atrophy. Since MuRF1 marks structural sarco-
meric proteins and initiates their degradation via the UPS its expression level is often used in 
diagnostics as marker in skeletal and heart muscle atrophy. Because MuRF1 plays a central 
role in the degradation process of structural proteins its transcriptional regulation was primari-
ly investigated in this study. Currently known pathways and associated transcription factors 
influencing MuRF1 expression were shown not to be responsible for all MuRF1 inductions 
observed in muscle atrophy. Especially the AngII triggered induction of MuRF1could not be 
explained until know. In addition to the identification of a new transcriptional regulator of 
MuRF1, its possible functional contribution in AngII triggered atrophy as well as its participa-
tion in pathways influencing skeletal muscle atrophy was addressed as secondary aims of this 
work.  
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2 Material and Methods  
2.1 Human adult skeletal muskle cDNA library screening 
A human male skeletal muscle cDNA library (Invitrogen, #11327-012) was titrated to achieve 
100 expressing cDNA plasmids per well. Titrated plasmid cDNA pools were co-transfected 
with the human -5002 bp (first screen) or 1006 bp (second screen) Hs_MuRF1-luc and 
pCMV-LacZ construct in COS-7 cells. For each well (96 format) 15000 COS-7 cells were 
transfected with 130 ng of pooled cDNA library together with 50 ng of Hs_MuRF1-luc re-
porter construct and 10 ng of pCMV-LacZ by using Fugene6 (Roche) according to the manu-
facturer’s instructions. 24 h after transfection the luciferase and fluorescence expressions were 
quantified as described in the next chapter (Luciferase and fluorescence quantification). Sub-
sequently, Sib-selection was performed to isolate single inducers of the Hs_MuRF1-luc con-
struct (illustrated in Figure 7, Results chapter). The number of used cDNAs per well was 
gradually reduced to 10 and finally one single cDNA per well to validate the initially ob-
served induction potentials. Inducing cDNA clones with induction levels over the plate’s dou-
ble positive SD mean value (2xSD+) were selected for further analysis. Single cDNAs acti-
vating the Hs_MuRF1-luc construct over 2xSD+ were verified by sequencing. 
2.2 Luciferase and fluorescence quantification 
Transfected cells (e.g. COS-7, HEK293 or C2C12, as indicated) were washed once with ice 
cold 1xPBS w/o MgCl2 (PAA H15-002), rinsed in 200 µL Reporter Lysis Buffer (RLB; 
Promega, E3971) and additionally lysed by snap freezing at -80°C for 10 min. The cell lysates 
were collected in 96 well plates and centrifugated at 1000 g for 2 min to pellet cell debris.   
The supernatant was transferred into new 96 well plates and used for quantification of lucifer-
ase activity and β-Galactosidase in a Fluostar Optima instrument (BMG-Labtech). For Lucif-
erase analysis 50 µL of supernatant were mixed with 50 µL of luciferase substrate solution 
(Promega E1501) within the Fluostar Optima instrument and for β-Galactosidase analysis 
10 µL lysates were analyzed with FluoReporter LacZ Galactosidase Quantification Kit (Invi-
trogen, F2905) according to the manufacturer instructions. 
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2.3 Indirect immunofluorescence microscopy  
For immunofluorescence microscopy cells were cultured onto glass cover slips, fixed with 4% 
Para-Formaldehyde (20 min 4°C), permeabilized with 0,1% Triton X-100 in 1x PBS 20 min 
RT, blocked with 5% serum corresponding to the secondary antibodies host and incubated 
with specific primary antibody at 4°C over night in H2O saturated atmosphere. After three 
times washing with 1xPBS, sections as well as cells were incubated with fluorescence cou-
pled secondary antibody. Pictures were recorded with the Leica CTR 6500HS and analyzed 
with Leica software LASAF 2.3.5 build 5379 Version 2010. Confocal microscopy was per-
formed with a Zeiss LSM 700 microscope and analyzed with Zeiss ZEN 2009 software.   
2.4 Protein extraction from tissue and Western blot analysis 
Briefly, biopsy specimens were homogenized in ice-cold extraction buffer (1:3 wt/vol; 10 mM 
Tris HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 25% glycerol, 0.5% sodium dodecyl sulfate 
(SDS), 0.5% Nonident P-40, 0.1 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 
100 ng/ml protease inhibitor cocktail) using FastPrep-24 instrument (MP Bio) according to 
the manufacturer’s instructions (30 s, 2000 rpm). After centrifugation at 18,700 x g (4 °C, 
10 min) protein concentration in the resulting supernatant was measured using a protein assay 
(Bio-Rad), before samples were stored at -80°C. Protein samples were separated by size using 
8, 10 or 15 % SDS polyacrylamide gel electrophoresis (SDS-PAGE) and blotted onto PVDF 
membranes (Amersham Pharmacia Biotech).  
2.5 Antibodies 
Following antibodies were used (for Western blot, Co-IP and ChIP analyses): anti-Tfeb goat 
(Abcam, ab2636 and  ab122910), anti-Goat-HRP (Abcam, ab6741), anti-GAPDH mouse 
(Millipore, MAB 374), anti-MuRF1 mouse (Abcam, ab57865), anti-MYC mouse (Millipore, 
05-419), anti-MYC rabbit (Upstate, 06-549), anti-FLAG rabbit (Cell Signaling, 2368), anti-
Mouse HRP (Cell Signaling, 7076), anti-rabbit HRP (Cell Signaling, 7074), anti-mouse 
AlexaFluor488 (Invitrogen, A11001) and anti-rabbit AlexaFluor488 (Invitrogen, A11008) 
antibody. 
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2.6 RNA Isolation, cDNA synthesis and real-time RT-PCR analysis 
RNA's were isolated using Trizol™ Reagent (Invitrogen, 15596-026) according to manufac-
turer instructions.  
Detailed protocol with variations of the manufacturer’s instructions: Cells from cell culture 
experiments or organ fragments isolated from animals were lysed after washing once with ice-
cold 1xPBS, by adding 1 mL (per 6 well) of Trizol reagent and passing several times through 
a 1 mL pipette tip. Resulted extract solutions from muscle cells and muscle tissue were pre-
cleared by an additional centrifugation strep at 4°C with 12,000 g for 10 min. The cleared 
supernatant was transferred to a fresh RNAse free tube, incubated for 5 min at RT. Phase 
separation has been started by supplementation with 200 µL pure chloroform per 1 mL of 
initially used Tritol and ongoing hand shaking for 15 seconds and incubation at RT for 2 to 3 
minutes. Separation was proceeded by centrifugation at 4°C with 12,000 g for 15 min. The 
resulting clear upper aqueous phase was transferred to a fresh RNAse free tube, RNA was 
precipitated by adding 0,5 mL of isopropyl alcohol (isopropanol) per 1 mL of Trizol Reagent 
used for initial homogenization, resulting samples were mixed by hand shaking and incubated 
for 10 min at RT. After centrifugation at 4°C with 12,000 g for 10 min the resulting pellet was 
washed with 1 mL 75% EtOH and again centrifuged at 4°C with 7,500 g for 5 min. RNA 
pellet was resolved in RNAse-free water after air-drying in sterile conditions and used for 
further analysis or stored at -80°C. RNAs from C2C12 myotubes following Tfeb siRNA 
treatment were isolated with RNeasy Mini Kit (Quiagen) according to the manufacturer in-
structions. 
For cDNA synthesis 1 µg of total RNA was transcribed using Superscript II reverse transcrip-
tase (Invitrogen, 18064-022) according to manufacturer instructions.  
Detailed protocol with variations of the manufacturer’s instructions: Transcription of 1 µg of 
total RNA in a final volume of 20 µL was started by adding 1 µL of 50 – 250 ng/µL random 
Oligos or Oligo dT 12-18mer (500 ng/µL) and 1 μL of dNTP Mix (10 mM each) to the RNA 
and filling up at 12 µL with RNAse free distilled water. Mixture was incubated at 65°C for 5 
min quick chilled on ice and 4 µL of 5x First Strand buffer, 2 µL of 0.1 M DTT and 1 µL of 
RNaseOUT (40 units/μL) were added and mixed. When using Oligo dT primers solution was 
incubated at 42°C for 2 min, or when using radom primers at 25°C for 2 min; after adding 1 
µL of SuperScriptII (200U) the mixture was incubated at 42°C for 50 min; when using 
random primers an additional pre-incubation at 25°C for 10 min was added. To deactivate the 
SuperScriptII enzyme an incubation at 70°C for 15 min was performed. The resulting cDNA 
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was used for further analysis or stored at 4°C for short term storadge or -20°C for long term 
storadge.   
For real-time RT-PCR analysis 10 ng of cDNA were used in a SYBR Green (ABI) based ap-
proach in a StepOnePlus™ Real-Time PCR System (Applied Bio Systems) according to the 
manufacturer’s instructions. Expression levels were correlated to Gapdh expression, aberra-
tions are indicated. Primer sequences are listed in table 1. 
Table 2: Real-Time PCR Primers used in this study 
Primer name  Sequence (5’ – 3’) 
Mm_Gapdh sense ATGGTGAAGGTCGGTGTGA 
 anti-sense AATCTCCACTTTGCCACTGC 
Mm_Tfeb  sense GAGCTGGGAATGCTGATCC 
 anti-sense CTTGAGGATGGTGCCTTTGT 
Mm_MuRF1  sense GATTATAAATCTAGCCTGATTC 
 anti-sense TTGGTGTTCTTCTTTACCCTC 
Mm_MuRF2  sense AGCACTTCTCTGAATTACAAG 
 anti-sense TTCATTTAGGGAATTCAACCAG 
Mm_MuRF3  sense AACTTCACGGTGGGTTTCAAGC 
 anti-sense GTGCAGGCCTGAGCCTTCTGGC 
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2.7 Mammalian expression vectors 
Table 3: Mammalian expression vectors used in this study 
Vector description Vector card 
pcDNA™3.1/myc-His(-) vectors (Invitrogen) 
Mammalian expression vector, the multiple clon-
ing site (MCS) is driven from a CMV promoter to 
obtain high expression of inserted gene transcript. 
The vector includes coding sequences (CDS) for 
Neomycin (for mammalian selection) and ampi-
cillin (for bacterial selection). The vector card is 
shown on the right side including the MCS and 
primers for sequencing. This vector was used as 
template for the manufacturing of the N-terminal 
FLAG tagged version, obtained from Jens Fielitz. 
 
pCMV SPORT6 (Invitrogen) 
Mammalian expression vector for SuperScript 
Pre-made cDNA library integration via Gateway 
Cloning procedure. The Gateway cloning site in 
between attB2 and attB1 is driven from a CMV 
promoter to obtain high expression of inserted 
gene transcript. The vector includes a CDS Am-
picillin (for bacterial selection). The vector card 
is shown on the right side including the MCS and 
primers for sequencing. 
 
pCMV-LacZ (Clontech) 
Mammalian expression vector encoding the 
β-Galactosidase gene which is regulated from the 
CMV promoter for high expression rates. The 
vector includes a CDS Ampicillin (for bacterial 
selection). In this study this vector was used as 
transfection control plasmid in luciferase assay 
co-transfection approaches. The vector card is 
shown on the right side including the MCS and 
primers for sequencing. 
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pZsGreen1-N1 (Clontech) 
Mammalian expression vector for fusion expres-
sion with the Zoanthus sp. green fluorescent 
protein, ZsGreen1 (excitation maximum = 496 
nm; emission maximum = 506 nm). The gene of 
interest is cloned into the MCS and regulated 
from the CMV promoter; the resulting protein 
contains an N-terminal fusion to the ZsGreen1 
protein. The vector includes a CDS of the Ampi-
cillin gene (for bacterial selection). The vector 
card is shown on the right side including the 
MCS. 
 
pGL3-Basic vector (Promega) 
This vector lacks eukaryotic promoter and en-
hancer sequences enabling the analysis of regula-
tory elements, cloned into the MCS, driving the 
firefly luciferase gene (luc+). The vector includes 
a CDS for Ampicillin (for bacterial selection). 
The vector card is shown on the right side includ-
ing single cutting restriction enzymes within the 
MCS. 
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2.8 Eukaryotic expression constructs 
Table 4: Eukaryotic expression constructs used in this study 
Name Insert Backbone Tag Source/Reference 
Hs_MuRF1-luc 
 
Human MuRF1 promoter 
sequence; mostly used 
size 543 bp upstream of 
the ATG 




Human MuRF1 promoter 
sequence; different 
clones with sizes from 
-5002 bp to -100 bp 
upstream of the ATG 
pGL3-basic none self made 
Hs_MuRF1-luc 
E-Box 1, 2, 3 
and 4 mutations 
Human MuRF1 promoter 
sequence; size 543 bp; 
individual mutations of 
the E-box motifs 1, 2, 3 
and 4 (CANNTG to 
ATNNTG) 
pGL3-basic none self made 
FLAG-Tfeb Mouse full length iso-
form 1 of the transcrip-





full length Tfeb from 
imaGenes 




tured via deletion-PCR 
of the full length FLAG-
Tfeb construct;  







full length Tfeb from 
imaGenes 
sub-cloning self made 
Tfeb Myc-His Mouse full length iso-
form 1 of the transcrip-
tion factor EB  
pcDNA3.1/myc-
His(-) A 
Myc – 6x His 
C-terminal  
Tfeb CDS from 
imaGenes 




Partial sequence of the 
human transcription 
factor EB coding se-
quence from cDNA li-
brary  
pCMV-SPORT6 none cDNA library from 
Invitrogen  
Tfeb-GFP Mouse full length iso-
form 1 of the transcrip-
tion factor EB;  





full length Tfeb from 
imaGenes 
sub-cloning self made 
FLAG-HDAC4 Full length coding se-





(Rick B. Vega et al., 
2004) 
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Ia HDAC4 
FLAG-HDAC5 Full length coding se-






(K. Song et al., 2006) 
HDAC5-Myc Full length coding se-
















(K. Song et al., 2006) 
FLAG-HDAC7 Full length coding se-






(Shurong Chang et al., 
2006) 
FLAG-HDAC9 Full length coding se-






(S. Chang et al., 2004) 
Myc-PKD1  Full length coding se-





(Kim et al., 2008) 
Myc-PKD1  
ca and dn 
Full length coding se-






(Kim et al., 2008) 
FLAG-PKD2 Full length coding se-








ca and dn 
Full length coding se-







FLAG-PKD3 Full length coding se-








ca and dn 
Full length coding se-







FLAG-MEF2A Full length coding se-






(Kim et al., 2008) 
Expression constructs encoding for ClassIIa HDAC 4, 5, 7 and 9 as well as PKD1 and its isoforms were de-
scribed recently as shown on the right side and were a kind gift from Eric N. Olson, Kunhua Song and Johannes 
Backs. 
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2.9 Expression plasmids and reporter gene assay construction 
The human MuRF1 promoter was amplified from genomic DNA, isolated from female human 
blood. The MuRF1 -5000 bp promoter fragment was cloned into pGL3 basic luciferase vector 
(Promega E1751) using the primers listed in table 5. The smaller MuRF1 promoter fragments 
were generated using the -5000 bp fragment as template.  
The MuRF1 promoter E-box mutations were generated using Phusion® Site-Directed Muta-
genesis Kit (Finnzymes, #F-541). Primers were designed according to manufacturer’s instruc-
tions to mutate the consensus E-box motif CANNTG to ATNNTG, primer sequences in pri-
mer table. All positive clones were verified by sequencing.  
Table 5: PCR Primers for cloning of human MuRF1-promoter and E-Box mutation PCRs 
Primer name  Sequence (5’ – 3’) 
Hs_E-Box 1 mut.  sense CCTCCTGGGGCTATTGTGACCAAGATC 
 anti-sense GATCTTGGTCACAATAGCCCCAGGAGG 
Hs_E-Box 2 mut.  sense CATCGGAATGCTATGCTGGTCCCCTC 
 anti-sense CCAAGCGGCTGGTGGGGCTTGAG 
Hs_E-Box 3 mut.  sense GATTGCTCATCCCTGATTGTGATTTGAGAG 
 anti-sense CTCTCAAATCACAATCAGGGATGAGCAATC 
Hs_E-Box 4 mut.  sense CTTGAATCCCCGTGGCTATCTTGCTGGGTCCCATCC 
 anti-sense GGGTTAATAGCCAATGCTATGATGAAAATGTTCGATGAATGA 
Hs_MuRF1-luc -5002 bp  sense (NheI) CTAGCTAGCAACAGGGCCATGTGAATGGC 
Hs_MuRF1-luc -3938 bp  sense (NheI) GTGCTAGCGCTGGGATTATAGGTGTGAGC 
Hs_MuRF1-luc -3500 bp  sense (NheI) GTGCTAGCGAGAATCATCAGCATATGG 
Hs_MuRF1-luc -2960 bp  sense (NheI) GTGCTAGCCTGAGGTCCCATGAGCAAGGAAG 
Hs_MuRF1-luc -1565 bp  sense (NheI) GTGCTAGCCAGGCGTGAGTCACTGTGCCC 
Hs_MuRF1-luc -1006 bp  sense (NheI) GTGCTAGCCCATTTCAAAATCTGTAAGATG 
Hs_MuRF1-luc -543 bp  sense (NheI) GTGCTAGCGTACTCAGAAAAATGTCTGATG 
pGL3 basic general 
reverse primer (XhoI) 
anti-sense CCGCTCGAGCATTCTGTGGGAAGGAATGA 
Hs_MuRF1-luc -400 bp sense GTGCTAGCGACCAATTTCTGGAGGAAG 
Hs_MuRF1-luc -300 bp sense GTGCTAGCGATTGCTCATCCCTGCATGTG 
Hs_MuRF1-luc -200 bp sense GTGCTAGCCTCCTGGGGCTCATGTGAC 
Hs_MuRF1-luc -100 bp sense GTGCTAGCACCCGGTGTTTTGTGACAAAG 
Mouse Tfeb cDNA was purchased from imaGenes (IRAVp968G09140D) and cloned into 
pcDNA™3.1myc-His6 (-A) (Invitrogen) providing a C-terminal myc-(His)6 tag fused to Tfeb 
with primers listed in table 6 as well as into pcDNA™3.1 FLAG providing an N-terminal 
FLAG-tag. For pZS-Green1N1 vector (Clontech) cloning, providing a ZsGreen1 fluorescent 
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fusion protein, Tfeb was amplified using primers also listed in table 6. Deletion mutants of 
Tfeb were generated by using Phusion® Site-Directed Mutagenesis Kit (Finnzymes) with the 
full length FLAG-Tfeb clone as template and primer sequences listed in table 6 as well. Posi-
tive clones were verified by sequencing. 
Table 6: Primers for Tfeb and deletion mutant construction cloning used in this study 
Primer name  Sequence (5’ – 3’) 
Tfeb pcDNA3.1 myc-His (-) A  sense (EcoRI) TGAATTCATGGCTCAGCTCGCTCAG 
 anti-sense (KpnI) CAGGTACCCAGAACATCACCCTCCTCCATGCT 
Tfeb pcDNA N-FLAG  sense (EcoRI) GGAATTCGCTCAGCTCGCTCAGTGGTCT 
 anti-sense (KpnI) GGGTACCTCACAGAACATCACCCTCCTCCATGC 
Tfeb pZsGreen1-N1  sense (NheI) CTAGCTAGCATGGCTCAGCTCGCTCAGTGG 
 anti-sense (XhoI) CCGCTCGAGCAGAACATCACCCTCCTCCA 
Tfeb 1-128  sense AAGGTGCAGTCCTACCTGGAGAAC 
 anti-sense ATCGATTTTATCGTCATCGTCTTTGTAGTCCAT 
Tfeb Δ129-237  sense ATGCCTAACACGCTGCCCCTG 
 anti-sense CAGCACCTCCCCGGGCACA 
Tfeb Δ238-400  sense CAGCAGGTGGTGAAGCAAGAGTTG 
 anti-sense CTGCATCTCAGGGTTGATGTAGCCCA 
Tfeb Δ299-352  sense TCCCGGCGCCTGGAGATGACT 
 anti-sense GTGATTGTCTTTCTTCTGCCGCTCCT 
2.10 Cell lines 
COS-7 cells (ATCC, CRL1651) and C2C12 cells (ATCC, CRL1772) were cultured in  low 
glucose DME-Medium (PAA, D6046) HEk293 in high glucose DME-Medium (PAA,D5796) 
both supplemented with 10% FBS (PAA, A15-104) and penicillin and streptomycin (PAA, 
P11-010) in a humidified 5% CO2 atmosphere at 37°C. For differentiation of C2C12 my-
oblasts 2x105 cells per well of a 6well-plate were seeded in 10%FBS DME-medium which 
was replaced 24h later by low glucose DME-Medium containing 2% FBS with penicillin and 
streptomycin (PAA, P11-010). Differentiation was performed for indicated time points with 
daily medium exchange. COS-7 cells were transiently transfected using FuGENE-6 (Roche) 
following manufacturers’ instructions, HEK293 cells were transiently transfected using poly-
ethylenimine (Polyscience Inc., #24313 linear MW2500) with DNA/PEI ratio of 1/3.  
2.11 siRNA transfection 
The mouse Tfeb ON-TARGETplus SMARTpool siRNA (Dharmacon, L-050607-01-0020) 
was used, optimization was performed using 5 to 100 ng (data not shown), and transfected 
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with Dhramafect3 reagent (Dharmacon, T-2003) according to the manufacturer’s instructions. 
As negative control the ON-TARGETplus Non-targeting siRNA Pool (Dharmacon, D-
001810-10-05) was used in the same concentration.  
2.12 Co-Immunoprecipitation (Co-IP) 
For Co-IP analysis HEK293 cells were transfected with 2 µg of total expression plasmid DNA 
per six-well, diluted in 200 µL serum-free medium (DMEM Low glucose) and 6 µL of 
polyethylenimin (PEI Stock 1µg/µL), well mixed solution’s were incubated for 30 min at RT. 
Transfected cells were washed with ice cold 1xPBS and isolated after 24 h of over expression 
by scraping cells in 200 µL precooled (4°C) potasium phosphat buffer (Co-IP buffer: potassi-
um-phosphate buffer pH 7,4; 150mM NaCl; 0,5% Triton X-100). Lysing was achieved by a 
following incubation at 4°C for 30 min in an overhead shacer. After centrifugation at 4°C with 
10,000 g the resulting supernatend was transfered into a fresh, precooled 1,5 mL tube, 
whereof 10% were seperated as input control. The precipitation was assembeled using equal 
amounts of each lysate, 30 µL prewashed and equilibrated M2-FLAG agarose resolved in 100 
µL Phosphat buffer containing 0,2 % Triton X-100 (Co-IP buffer 0,2%); mixture was filled up 
with Co-IP buffer w/o triton X-100 up to 1 mL and incubated at 4°C in an overhead shacer at 
low speed (10 rpm) for 2 h. After washing 3 times with Co-IP buffer w/o triton X-100 by 
centrifugation at 4°C with 800 g for 3 min, the resulting agarose beats were sucked dry with a 
fine (40 gauge) needle, supplemented and resuspend with 2 x Lämli without beta-
mercaptoethanol and boiled for 3 min at 95°C. After short centrifugation, the eluate contain-
ing supernatant was transferred into a fresh tube, supplemented with 3 µL of 100% beta-
mercaptoethanol and boiled for additional 7 min at 95°C. Input and Co-IP eluate of each ex-
periment were analyzed using SDS-PAGE protein separation and following antibody detec-
tion.  
2.13  Chromatin-Immunoprecipitation (ChIP) 
For ChIP experiments, 7,5x105 C2C12 cells were seeded into 10 cm dishes and after 24 h a 
transient transfection or indicated treatment were performed. After incubation for indicated 
time of treatment or over expression, cells were cross-linked with 1% formaldehyde for 8 min 
at room temperature. Fixation was stopped by adding 2.5 M glycine to a final concentration of 
100 mM and incubation of 10 min at room temperature. Cells were harvested and washed 
three times with ice cold 1xPBS containing proteinase inhibitors (Roche) and centrifuged at 
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4000 x g for 5 min at 4 °C. Cell pellets were resuspended in SDS ChIP lysis buffer (10 mM 
EDTA, 50 mM Tris pH 8.1, 1% SDS) to a final concentration of 5*106cells/mL. For cell lysis 
cell-suspension was passed 10 times through a 27 gauge needle (Braun, size 20) and sonicated 
(Hielscher, UP50H) with conditions that consistently lead to DNA fragment sizes of 100-500 
Bp. Following centrifugation (13,000 x g, 10 min and 4 °C) 50 µL of clarified chromatin was 
used as Input control and 100 µL for immunoprecipitation. Clarified chromatin was diluted 
1:10 with of ChIP RIPA buffer containing 0,1% SDS and incubated with 30 µL of prewashed 
anti-FLAG M2 agarose beats (Sigma, A2220) for 2 h at 4°C. Coupled protein-DNA complex-
es were washed twice in low salt buffer (0,1% SDS, 1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl pH 8.1, 150mM NaCl), twice in high salt buffer (as low salt, but 500mM NaCl) and 
twice in TE buffer (10mM Tris HCl pH 8.8, 1mM EDTA). Elution was performed by using 55 
µL TE buffer with 1% SDS at 65°C and shaking at 1200 rpm for 10 min. 50 µL of eluate and 
input were supplemented with 150 µL TE, 5µL 10% SDS and 1µL RNAse (Fermentas, 
EN0541) and incubated for 30 min at 37C°. Proteins were afterwards digested by adding 5 µL 
of Proteinase K (20 µg/µL, VWR, 1.245.680.500) and lysates were incubated for 6 h at 37 °C 
and 6 h at 65 °C. DNA was isolated using DNA purification columns (Macheray Nagel, 
740609, NT buffer 740595) as described by the manufacturer. Input DNA was eluted in 200 
µL and ChIP DNA was eluted in 50 µL H2O whereof 5 µL were used for each Real-Time PCR 
detection. 
Table 7: Primers for Real-Time detection of ChIPed mouse MuRF1-promoter E-Box sites 
Primer  Sequence (5’ – 3’) 
Mm_MuRF1 E-box 1 (-30 bp) sense GTGGGTTTGGAGACAAAGAC 
 anti-sense ATTGCTTTGAAATGCGACTGT 
Mm_MuRF1 E-box 2 (-151 bp) sense TCCTGGGGCTCATGTGAC 
 anti-sense CCCTCTGATATTTATAGCTGCAC 
Mm_MuRF1 E-box 3 (-173 bp)  sense CTCAAGCCCTGCCAGCAG 
 anti-sense CAGGAGGGGACCAGCTG 
Mm_MuRF1 E-box 4 (-250 bp)  sense CAACAGCGATTGCTCATCCC 
 anti-sense AAGATTTGGCCCTCTCAGATC 
Base indications of E-box primer positions refer to the genomic mouse sequences of MuRF1-promoter upstream 
of the ATG start codon. These positions do relatively differ from human E-box positions. 
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3 Results 
3.1 MuRF1-promoter screening 
The main focus of this research project was to identify new transcriptional regulators of the 
MuRF1 gene. To identify novel regulators of MuRF1 two independent screening procedures, 
using 5002 base pairs (bp) and 1006 bp of the human MuRF1 promoter (M1P, Table 4), were 
separately performed using a human skeletal muscle derived cDNA library. After screening a 
total number of about 114,000 cDNA clones by sib selection (fractionation based isolation of 
a particular cDNA library clone which shows positive induction; working scheme illustrated 
in Figure 7). Finally purified and isolated cDNAs were identified by sequencing. A total 
number of 34 cDNA clones activating the M1P construct, with partial (P) or full-length (FL) 
coding sequences (CDS), were obtained from both screening procedures. In total, five identi-
fied clones were previously described as transcription factors or linked to transcriptional acti-
vation. One hit was previously described as transcriptional repressor.  
Following the studies main focus, the strongest inducers were analyzed in dose dependent 
verification assays. The most interesting looking candidates, which showed dose dependent 
M1P construct inductions, were cloned into expression plasmids as full-length isoforms. Dur-
ing the screening process the transcription factor EB (TFEB) was identified as most potent 
regulator of the M1P construct and was found six times in both screenings.  
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Figure 7: Schematic illustration of cDNA library screening procedure 
The upper figure panel (A) shows the general plasmids used in the screening transfection approach. Left plas-
mid: CMV-promoter driven, containing cDNA library derived from adult human skeletal muscle mRNA tran-
scripts (from Invitrogen); Middle plasmid: pGl3basic vector (Promega), containing MuRF1 promoter sequence 
amplified from human genomic DNA driving luciferase gene, used for quantification of promoter activity; Right 
plasmid: CMV-promoter, controlling beta-Galactosidase gene expression, used as constitutive active transfec-
tion control, measured via fluorescence quantification. Lower panel (B) shows the underlying cell culture proce-
dure. The cDNA library was titrated to an initial average concentration of 100 CFU/well (or different cDNA 
clones/mini-prep) during plasmid preparation from BAK clone library. For detailed transfection information see 
Material and Methods. After subsequent cDNA count reduction single clone candidates were identified by se-
quencing. 
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Figure 8: Luciferase assay read-outs from cDNA library screening procedure of human MuRF1-promoter 
(A) Graph shows representative quantifications of one initial screening plate, corresponding to ~100 cDNAs per 
well of cDNA library derived from human skeletal muscle mRNA. (B) Graph shows final screening phase, after 
sib selection, whereas each bar represents M1P construct inductions by a single cDNA clone, subsequently ex-
tracted from initial round shown in A. Arrow indicates well/peak containing a sequence-verified partial TFEB 
cDNA clone. Relative calculations are shown in luciferase/fluorescence ratio, corresponding to cDNA clone 
induced M1P construct and the fluorescence quantification of the transfection control plasmid pCMV-LacZ. 
Black continuous lines indicate the plates doubled average SD values (+2xSD) whereas dotted lines indicate the 
plates mean values. (Ref.: Figure data are included in manuscript in preparation/submission) 
 
Sequencing of the cDNA library encoded pSPORT6-TFEB constructs revealed that two dif-
ferent isoforms of TFEB were isolated during the screening process. One encoded a full 
length version in accordance with the human TFEB Isoform 1. The second isoform encoded 
for a partial cDNA fragment ranging from amino acids 96 to the C-terminal end of the full 
length human TFEB protein (Figure 9), when compared with the longest human TFEB iso-
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form 2 (accession NM_1167827.2; (Carr & Sharp, 1990)). However, the shorter isoform iden-
tified here contains all of the annotated domains, such as the activation (AD), basic helix-
loop-helix (bHLH), leucine-zipper (LZ) and DUF3371 (DUF) domain.  
 
 
Figure 9: Illustration of the human TFEB Isoforms 1, 2 and 3 plus the identified clone from cDNA library 
screening.  
The human TFEB Isoforms 1, 2 and 3 encoding transcript variants 1 to 5 are indicated at the right side. Graph-
ical explanations: (AD) activation domain, (bHLH) basic helix-loop-helix domain, (LZ) leucine-zipper domain 
and DUF3371 domain. Number of amino acids is shown under the C-terminal end of each isoform. Sections in 
yellow and violet are marked for better orientation and do not represent annotated domains or regulatory regions.  
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3.2 Identification of binding site for Tfeb of MuRF1 promoter 
Comparing the longest isoforms of human TFEB Iso 2 (490 AA) and mouse Tfeb isoform A 
(534 AA), both protein sequences disclosed a 93 % sequence identity (Sequence-alignment in 
appendix figure 1). Since direct amplification of the full length mouse Tfeb from muscle tis-
sue derived cDNA was without any result, a purchased Tfeb (mouse isoform A) from 
ImaGenes was used. The obtained full length Tfeb was cloned in an N-terminal FLAG tag 
expression vector (FLAG-Tfeb, Table 3 and 4). Tfebs’ ability to dose dependently induce the 
M1P construct (size -543 bp, Table 4) could be confirmed when co-transfected in COS-7 cells 
(Figure 10). Luciferase assays, utilizing subsequently size-reduced M1P fragments from 
-5002 bp to -543 bp upstream of the MuRF1 transcriptional start codon, showed comparable 
fold activations (Figure 11 A). Further decrease of the M1P fragment from -300 bp to -200 bp 
strongly reduced Tfeb induced M1P expression declining from ~100 to ~10 fold (Fig-
ure 11 B). These results pointed towards a strong Tfeb regulatory element close to the tran-
scriptional start codon of MuRF1. It is noteworthy, that differences observed in maximum 
M1P construct inductions are partially based on variations in transfection efficiencies of dif-
ferentially used cell lines.  
 
Figure 10: Dose dependent MuRF1-promoter activation by Tfeb 
(A) COS-7 cells were co-transfected with the M1P construct (size -543 bp), pCMV-LacZ control plasmid and 
increasing amounts of FLAG-Tfeb expression plasmid (dose: 6, 25 – 100 ng). Values were normalized to basal 
expression of the M1P construct and calculated as fold-activation ratio (set to 1) of FLAG-Tfeb induced reporter 
(luciferase) to pCMV-LacZ (β-Gal). Graph shows representative experiment in triplicates, experiment has been 
performed at least three times. Error bars represent SD. Students T-Test, ** p < 0.005; *** p < 0.001. (Ref.: 
Figure data are included in manuscript in preparation/submission) 
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Figure 11: Size dependent MuRF1-promoter activation by Tfeb 
(A) Graph shows luciferase assay readouts, performed in HEK293 cells, of decreasing Hs_MuRF1-luc promoter 
fragment lengths (-5002 to -543 bp of Hs_MuRF1-promoter; pGL3basic equates empty luciferase reporter plas-
mid), co-transfected with 100 ng of FLAG-Tfeb expression plasmid. Values were normalized to basal expression 
of the M1P construct (size -543 bp) and calculated as fold-activation ratio of FLAG-Tfeb expression plasmids 
induced reporter relative to pCMV-LacZ (β-Gal). Graph shows representative experiment in triplicates, experi-
ment has been performed at least three times. Error bars represent SD. Students T-Test, ** p < 0.005; *** p < 
0.001. (B) Graph shows luciferase assay readout from HEK293 cells, co-transfected with Tfeb expression plas-
mids (FLAG-Tfeb), pCMV-LacZ transfection control plasmid and indicated decreasing M1P constructs (-543to -
100 base pairs of Hs_MuRF1-promoter; pGl3 basic equates empty luciferase reporter plasmid). Values were 
normalized to basal expression of the M1P construct (size -543 bp) and calculated as fold-activation ratio of Tfeb 
expression plasmids induced reporter relative to pCMV-LacZ (β-Gal). Graph shows representative experiment in 
triplicates, experiment has been performed at least three times. Error bars represent SD. Students T-Test, * p < 
0.05; ** p < 0.005; *** p < 0.001. (Ref.: Figure data are included in manuscript in preparation/submission) 
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Tfeb contains a bHLH DNA binding domain (Figure 9), which mediates E-box specific pro-
moter binding (E-box motive CANNTG; Figure 12 A). After literature reviewing (Fisher, 
Carr, Parent, & Sharp, 1991; Kuiper, Schepens, Thijssen, Schoenmakers, & van Kessel, 2004) 
and additive analysis of the MuRF1 promoter’s structure, including various mammalian spe-
cies, the conserved E-box binding motives within the M1P construct (size -543 bp) were indi-
vidually mutated (Figure 12 B; mutation CANNTG to ATNNTG). Mutation of the first and 
third E-box motives lead to a strong reduction of Tfeb mediated M1P expression. In contrast, 
mutation of the second E-box motif only moderately reduced luciferase expression. Surpris-
ingly, mutation of the lesser conserved forth E-box motif at position -299 to -304 in the hu-
man M1P construct produced an increase in Tfeb mediated M1P expression (Figure 12 B). 
This forth E-box position was excluded from further analysis due to lower species conserva-
tion and the main focus of this study, the investigation of positive regulators of MuRF1 ex-
pression.  
 
Figure 12: Tfeb regulates MuRF1 expression via E-box motives 
(A) Schematic diagram of MuRF1 promoter E-box conservation. E-box elements in the human MuRF1 promoter 
are indicated in purple relative to the transcription start codon (ATG). Underlying alignment shows genomic 
homology of individual E-box motifs in the MuRF1 promoter sequence of Homo sapiens, Mus musculus, Rattus 
norvegicus, Bos tauros and Sus scrofa. (B) Luciferase assay readouts from COS-7 cells co-transfected with 
FLAG-Tfeb construct, wild type (upper lane) and E-box mutated M1P constructs and the pCMV-LacZ (β-Gal). 
Values were normalized to basal expression of WT M1P construct expression (set to 1, not shown) and calculat-
ed as fold-activation ratio of luciferase to β-Gal. Each well contained same amounts of FLAG-Tfeb expression 
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plasmid. Mutations of the E-box motives (E-box 1 to E-box 4; CANNTG to mutant ATNNTG) are indicated. 
Error bars represent SD; n = 3; Students T-Test; * p < 0.05; ** p < 0.005; *** p < 0.001. (Ref.: Figure data are 
included in manuscript in preparation/submission) 
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3.3 Tfeb: Gain-of-function 
Potential influence of Tfeb over-expression onto the gene expression of the other MuRF fami-
ly members Trim55 encoding MuRF2 and Trim54 encoding MuRF3 was quantized by Re-
al-Time PCR (RT-PCR). Transfection of C2C12 myoblasts with a cDNA expression plasmid 
encoding FLAG-Tfeb resulted in a significant increase in MuRF1 expression (~10 fold), 
whereas no change was observed for MuRF2 or MuRF3 (Figure 13 A). In addition, lysates of 
identical treated C2C12 myoblasts showed increased MuRF1 protein content after 24 h of 
Tfeb over-expression in Western blot analysis (Figure 13 B). The increase in gain-of-function 
experiments of MuRF1 mRNA and MuRF1 protein contents confirmed that Tfeb regulates 
endogenous MuRF1.  
 
Figure 13: Tfeb regulates endogenous MuRF1 expression in C2C12 myoblasts 
(A) RT-PCR analysis of MuRF1, MuRF2 and MuRF3 expression in C2C12 myoblasts following overexpression 
of FLAG-Tfeb plasmid or a control plasmid for 24 h. Glyceraldehyde-3 phosphate dehydrogenase (GAPDH) 
expression was used as reference. Gene expression following control plasmid transfection was set to 1. Error 
bars represent SD. n.s. = not significant. ** p < 0.005; n = 3 for each sample. (B) C2C12 myoblasts were trans-
fected with expression plasmids encoding FLAG-Tfeb or a control protein for 24 h, and immunoblot analysis 
was performed with the antibodies indicated. (Ref.: Figure data are included in manuscript in prepara-
tion/submission) 
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3.3.1 Tfeb binds to the MuRF1 promoter via E-box motives 
To confirm Tfebs’ binding to the endogenous MuRF1 promoter sequence, Chroma-
tin-Immunoprecipitation (ChIP) experiments were performed in C2C12 myoblasts. ChIP 
analysis followed by RT-PCR showed that over-expressed N-FLAG or C-terminally Myc 
tagged full length Tfeb (Table 4) binds to the endogenous MuRF1 promoter sequence in 
C2C12 myoblasts (Figure 14 A and B). Both ChIP experiments showed an enrichment of the 
mouse MuRF1 promoter sequence when Tfeb was present, compared to the empty vector 
transfections. Due to the very close proximity of the E-box motives in the MuRF1 promoter 
sequence a clear distinction between individual E-box motifs was impossible (Fig-
ure 14 A, upper illustration). 
 
Figure 14: Tfeb binds to the endogenous MuRF1 promoter sequence 
(A) Representative Chromatin-Immunoprecipitation (ChIP) experiment performed with chromatin from C2C12 
myoblasts after overexpression of Tfeb Myc-His construct for 24 h (Tfeb Myc-His, Table 4). Chromatin was 
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immunoprecipitated with anti-Tfeb vs. IgG rabbit antibody (1 µg per IP) and Agarose-G beats. For eluate analy-
sis, E-box flanking primers (positions illustrated above) specific for the mouse MuRF1 promoter were used in 
Real-Time PCR based quantification. Results were calculated using deltaInput - deltaIgG - deltavector cT method. (B) 
Representative ChIP experiment of chromatin from C2C12 myoblasts after overexpression of FLAG-Tfeb con-
struct for 24 h (FLAG-Tfeb, Table 4). Cells were grown in normal growth DME-Medium (10 % FBS). Chroma-
tin was immunoprecipitated using M2 FLAG-Agarose. For eluate analysis, E-box flanking primers (positions 
illustrated in Figure 14 A) specific for the mouse MuRF1 promoter were used in Real-Time PCR based quantifi-
cation. Results were calculated using deltaInput - deltavector cT method. (Ref.: Figure data are included in manu-
script in preparation/submission) 
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3.4 Tfeb loss-of-function and functional involvement in starvation 
induced myotube formation   
Loss-of-function approaches, using siRNA mediated knock-down of Tfeb mRNA, in C2C12 
myoblasts and differentiated myotubes were performed to confirm the results from gain-of-
function and ChIP experiments. Knock-down of Tfeb for 24 h via specific siRNA transfection 
(100 nM each) in C2C12 myoblasts led to a decrease in MuRF1 mRNA and protein contents 
compared to siScr control treated cells (Figure 15 A and B). 
 
Figure 15: Knockdown of Tfeb influence endogenous MuRF1 expression 
(A) C2C12 myoblasts were transfected with scrambled control siRNA (siScr) or siRNA against Tfeb (siTfeb; 
100 nM each. Cells were harvested 24 h after transfection for immunoblot analysis of Tfeb, MuRF1 and Glycer-
aldehyde-3 phosphate dehydrogenase (GAPDH) protein content. (B) C2C12 myoblasts were treated as described 
for A. Cells were harvested 24 h after transfection and Tfeb and MuRF1 expression were quantified using RT-
PCR analysis. GAPDH expression was used as reference. Error bars represent SD. * p < 0.05; *** p < 0.001; n = 
3. (Ref.: Figure data are included in manuscript in preparation/submission) 
When identically treated C2C12 myoblasts were subsequently treated with differentiation 
medium (2 % FBS containing DME-medium) for 5 days, a diminished tube formation was 
observed, as determined by counting of myotubes (Figure 16 A and B). Reduced myotube 
formation was supported by a decrease in myosin fast protein content detected by Western-
blotting (Figure 17 A), which is observed only in differentiated myocytes. 
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Figure 16: Knock-down of Tfeb reduces C2C12 myotube differentiation 
(A and B) C2C12 myoblasts were transfected with scrambled control siRNA (siScr) or siRNA against Tfeb (siT-
feb; 100 nM each), as indicated. Cells were switched to differentiation conditions 24 h after transfection and diff. 
Medium (2 % FBS DME-medium) was changed every day. After 5 days of differentiation, cells were harvested 
and analyzed. (A) Representative graphical representation of C2C12 cells after siRNA knock-down described 
above. Scale bar represents 100 µm. (B) Graph shows myotube quantification from ten randomly taken pictures 
per group from same experimental setup as described above. Error bars represent SD. Student T-Test; *** p < 
0.001. (Ref.: Figure data are included in manuscript in preparation/submission) 
In addition, siTfeb pre-treated and differentiated C2C12 myotubes showed a decreased 
MuRF1 mRNA expression when compared with siScr control after 5 days of differentiation 
(Figure 17 B). This finding was supported by ChIP analysis. An enriched binding of endoge-
nous Tfeb to the endogenous MuRF1 promoter sequence was observed in ChIP analysis of 
6 hr serum starved (2 % FBS containing DME-medium) C2C12 myoblasts (Figure 18). 
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Figure 17: Tfeb knock-down reduces fast myosin and MuRF1 expression during C2C12 myotube differen-
tiation 
(A and B) C2C12 myoblasts were transfected with scrambled control siRNA (siScr) or siRNA against Tfeb 
(siTfeb; 100 nM each), as indicated. Cells were switched to differentiation conditions 24 h after transfection and 
diff. Medium (2 % FBS DME-medium) was changed every day. After 5 days of differentiation, cells were har-
vested and analyzed. (A) Western-blot analysis of differentiated C2C12 cells, proteins were detected by im-
munoblot analysis against fast-myosin, Tfeb and Gapdh. (B) Real-Time PCR analysis of MuRF1 expression in 
C2C12 cells, treated as described above. GAPDH expression was used as reference. Error bars represent SD. 
Students T-Test; *** p < 0.001; n = 3. (Ref.: Figure data are included in manuscript in preparation/submission) 
 
 
Figure 18: Enhanced Tfeb binding to the MuRF1 promoter after serum starvation 
Graph shows representative ChIP analysis of C2C12 myoblast chromatin of control cells, grown in normal 
growth DME-medium (10 % FBS) or serum starved cells (6 h; 2 % FBS DME-medium). Chromatin was incu-
bated with anti-Tfeb vs. IgG rabbit antibody (1 µg per IP) and immunoprecipitated using Agarose-G beats. For 
analysis, E-box flanking primers, specific for the mouse MuRF1 promoter, were used in RT-PCR quantification. 
Calculation was carried out using deltaInput - deltaIgG - deltastarvation cT method. (Ref.: Figure data are included in 
manuscript in preparation/submission) 
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3.5 Tfeb is negatively regulated by class IIa HDACs  
Now assuming that Tfeb plays a role in the regulation of MuRF1 expression, participation of 
Tfeb in known regulation pathways of skeletal muscle atrophy was taken into focus. One of 
the major and most potent regulators described for MuRF1 expression are the class IIa 
HDAC, shown to inhibit MuRF1 expression under different conditions (Viviana Moresi et al., 
2010b). All class IIa HDACs (HDAC4, 5, 7 and 9) were found to reduce basal expression of 
the M1P construct (size -543 bp) when co-transfected in COS-7 cells (Figure 19 A). To inves-
tigate if class IIa HDACs inhibit Tfeb induced MuRF1 expression (Hs_MuRF1-luc also M1P; 
size -543 bp) FLAG-Tfeb expression plasmid was transfected together with increasing 
amounts of HDAC4, 5, 7 and 9 expression plasmids and reporter assays were performed. The 
strongest negatively regulating effects unto the Tfeb mediated M1P inductions were observed 
for HDAC4 and 5 (Figure 19 B).   
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Figure 19: Repressive effect of ClassIIa HDACs on MuRF1 basal expression and Tfeb mediated induction 
(A) Graph shows luciferase assay quantification of co-transfected COS-7 cells with the M1P construct (size -543 
bp), pCMV-LacZ transfection control plasmid and indicated ClassIIa HDAC4, 5, 7 and 9 expression plasmids. 
Values were normalized to basal expression of M1P construct and calculated as fold-activation ratio of reporter 
to pCMV-LacZ (β-Gal). Graph shows representative experiment in triplicates, experiment has been performed at 
least three times. Error bars represent SD. Student T-Test; ** p < 0.005; *** p < 0.001. (B) Graph shows lucifer-
ase assay quantification of co-transfected COS-7 cells with the M1P construct (size -543 bp), pCMV-LacZ trans-
fection control plasmid, FLAG-Tfeb expression plasmid (100 ng per well) and increasing doses of indicated 
ClassIIa HDAC4, 5, 7 and 9 expression plasmids (dose range from 5 to 100 ng per well). Values were normal-
ized to basal expression of M1P construct and calculated as fold-activation ratio of reporter to pCMV-LacZ (β-
Gal). Graph shows representative experiment in triplicates, experiment has been performed at least three times. 
Error bars represent SD. Students T-Test; ** p < 0.005; *** p < 0.001. (Ref.: Figure data are included in manu-
script in preparation/submission) 
If the repression of Tfeb induced MuRF1 expression was mediated due to direct binding of 
Class IIa HDACs to Tfeb co-immunoprecipitation (Co-IP) experiments were performed of 
lysates from HEK293 cells co-transfected for 24 h with Tfeb Myc-His construct and FLAG-
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HDAC constructs. Indeed, Tfeb physically interacted with the ClassIIa HDAC5 (Figure 20 A 
and Figure 21 B). Next, it was investigated if this interaction could also be observed in cells, 
using co-localization studies performed in C2C12 myoblasts. It was found that Tfeb-GFP 
co-localized with FLAG-HDAC4 and FLAG-HDAC5 (stained with Alexa 555), respectively. 
This co-localization occurred in nuclei (Figure 20 B) and in cytoplasmic vesicular structures 
(Figure 21 C; constructs in Table 4).  
 
Figure 20: Interaction and Co-localization of Tfeb with ClassIIa HDAC family members 
(A) Western-blot analysis showing inputs (both upper panels, anti Myc and anti FLAG) and eluates (lower panel, 
anti Myc) of co-immunoprecipitation experiment performed in HEK293 cells, over-expressing Tfeb Myc-His 
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expression plasmid and FLAG-HDAC4, 5, 7 or 9 expression plasmids (used constructs in Table 4). Inputs repre-
sent 10% of total lysates. Left panel represents negative control with empty FLAG vector. (B) Graphical repre-
sentation of co-localization study performed in C2C12 myoblasts, over-expressing Tfeb-GFP and FLAG-tagged 
HDAC4, 5, 7 and 9 expression plasmids as indicated. Left panel (red signal) shows HDAC signal detected by 
immunostaining (secondary antibody Alexa 555, primary anti FLAG M2). Green signal shows GFP signal from 
Tfeb-GFP construct. The third panel from left represents merged overlays of red and green channels with marked 
nuclei in white boxes representing magnified area shown in C. Right panel in B shows merged channels plus 
DAPI signal overlay. Scale bars represent 10 µm. (C) Magnifications of marked nuclei shown in B. White ar-




Figure 21: Inhibition of the Tfeb mediated MuRF1 induction by ClassIIa HDAC5 
(A) HEK293 cells were transfected with expression plasmids encoding full length Tfeb and HDAC5 together 
with the M1P construct (size 543 bp), as indicated. Values were normalized to pCMV-LacZ transfection control 
vector expression and calculated as fold-activation in luciferase to pCMV-LacZ ratio compared to the reporter 
alone. Error bars represent SD. Students T-Test; *** p < 0.001. n = 3. (B) HEK293 cells were transfected with 
expression plasmids encoding FLAG-Tfeb and HDAC5-myc (above panel) and Tfeb-myc and FLAG-HDAC5 
(lower panel). Inputs of Tfeb and HDAC5 proteins detected by immunoblot (IB) are shown in the top and middle 
panels. Inputs represent 10% of total lysates. Co-immunoprecipitated proteins are shown in the bottom panels. 
(C) C2C12 myoblasts were co-transfected with expression plasmids encoding Tfeb-GFP and HDAC5-myc. 
HDAC5 was detected by immunostaining (Alexa 555) and Tfeb by GFP fluorescence using confocal microsco-
py. Scale bar in left picture represents 10 µm. Augmentations of indicated regions (a and b) are shown in smaller 
panels to the right. Scale bar represents 5 µm. Arrowheads in a indicate areas of co-localization. (Ref.: Figure 
data are included in manuscript in preparation/submission) 
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3.6 Mapping of Tfeb and HDAC5 interaction 
To characterize the interaction between Tfeb and HDAC5 in more detail, deletion mutants of 
both cDNAs were generated and used in Co-IP and luciferase assays. Co-IP experiments indi-
cated that the HDAC5/Tfeb interaction was mediated via the N-terminal end of HDAC5 (Fig-
ure 22 A and B; constructs in Table 4). Because interaction of HDAC5 and Tfeb was still pre-
sent when deletion mutant HDAC5 51-C was used, but disappeared with HDAC5 mutant 100-
C, it was assumed that amino acids 51 to 100 of the HDAC5 protein are responsible for inter-
action with Tfeb (Figure 22 A and B). These findings are further supported by luciferase as-
say analysis. More specifically, deletion of the first 51 amino acids of HDAC5 did not influ-
ence its ability to inhibit Tfeb mediated MuRF1-luc induction (Figure 22 C). However, larger 
deletion of the N-terminal region in HDAC5, using HDAC5 100-C and HDAC5 175-C ex-
pression plasmids, abolished Tfeb induced MuRF1 expression (Figure 22 C). In addition, 
when the HDAC domain in HDAC5 was deleted (using the C-terminal deletion clone 
HDAC5 1-664) no decrease of Tfeb mediated MuRF1 expression was observed, indicative for 
the importance of the HDAC domain for its repressive function (Figure 22 C). Interaction of 
full length Tfeb with HDAC5 1-664 could still be observed (Figure 22 B). These findings 
implicate a direct interaction of both proteins mediated by amino acids 51 to 100 of HDAC5. 
These data also show that HDAC5 mediated inhibition of Tfeb induced MuRF1 expression is 
mediated by its HDAC domain. 
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Figure 22: Functional mapping of HDAC5 deletion mutants with full length Tfeb 
(A) Schematic illustration of HDAC5 deletion mutant clone design. Binding domains for Tfeb (red) and PKD1 
(yellow) as well as nuclear localization signal (NLS, in green) and HDAC family domain (orange) are plotted. 
Figure’s information were partially adopted from Zhang et al. 2002 and from own manuscript in preparation. 
Interaction of individual deletion clones with full length Tfeb in Co-IP assay, shown in B, is indicated at the 
right side. (B) HEK293 cells were transfected with expression plasmids encoding full length FLAG-Tfeb and 
HDAC5-myc full length or deletion clone plasmids as indicated. Input Tfeb and HDAC5 proteins detected by 
immunoblot (IB) are shown in the top and middle panels. Inputs represent 10% of total lysates. Co-
immunoprecipitated eluates representing HDAC5 deletion clones are shown in the bottom panel. (C) HEK293 
cells were transfected with expression plasmids encoding FLAG-Tfeb and full length or mutant HDAC5 expres-
sion plasmids, as indicated, and M1P  (size -543 bp). Values were normalized to expression of pCMV-LacZ and 
calculated as the fold-activation in luciferase to pCMV-LacZ ratio compared to the reporter alone. Error bars 
represent SD. * p < 0.05; ** p < 0.005; *** p < 0.001; n = 3. (Ref.: Figure data are included in manuscript in 
preparation/submission) 
Next step was the determination of the region in Tfeb which mediates its interaction with 
HDAC5 (Figure 23 A, constructs in Table 4). Tfeb deletion mutants were designed according 
to the known domain structure of mouse Tfeb; this included the bHLH and the LZ domain. 
The N-terminal deletion clone, lacking the first 127 amino acids (Tfeb 128-C), which includes 
a glycine rich region with unknown function, did not interact with full length HDAC5 in Co-
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IP experiments (Figure 23 B). This clone showed a reduced effectiveness in M1P construct 
(size -543 bp) induction, and was less sensitive to HDAC5 in luciferase assays (Figure 23 C). 
Similar results were observed for the Tfeb deletion mutant Δ129-237, showing no interaction 
with HDAC5 and comparable induction of the MuRF1-luc activity (Figure 23 B and C). The 
other two internal deletion clones Tfeb Δ238-400 and Tfeb Δ299-352 were amongst others 
designed to confirm Tfebs’ MuRF1 induction via the bHLH DNA binding domain. Tfeb 
Δ238-400, which comprised the bHLH and the LZ domain, showed stable interaction with 
HDAC5 in Co-IP experiments (Figure 23 B). As expected, this deletion mutant was unable to 
induce MuRF1 expression (Figure 23 C). Tfeb Δ299-352, missing the amino acids encoding 
for the bHLH domain, retained its interaction capacity with HDAC5 (Figure 23 B) and was 
also unable to increase MuRF1 expression (Figure 23 C). In addition, this expression plasmid 
did not induce MuRF1 at protein level when transfected in C2C12 myoblasts compared to 
wild type full-length Tfeb (Figure 23 D).   
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Figure 23: Functional mapping of Tfeb deletion mutants with full length HDAC5 
(A) Schematic illustration of full length mouse Tfeb isoform A (Q6P203) and deletion mutants used in this 
study. Deletion-clone nomenclature is shown on left side. Indicated domains and regions: GR = Glycine-rich, 
violet box; bHLH = basic Helix-Loop-Helix domain, green box; LZ = Leucine Zipper domain, blue box. (B) 
HEK293 cells were transfected with expression plasmids encoding full length HDAC5-myc and full length or 
mutant FLAG-Tfeb proteins as indicated. Input HDAC5 and full length and mutant Tfeb proteins detected by 
immunoblot (IB) are shown in the top and middle panels. Inputs represent 10% of total lysates. Co-
immunoprecipitated eluates representing HDAC5 are shown in the bottom panel. (C) HEK293 cells were trans-
fected with expression plasmids encoding full length or mutant Tfeb or full length histone deacetylase (HDAC) 5 
at equal amounts and the M1P reporter construct (size -543 bp). Values were normalized to expression of 
pCMV-LacZ and calculated as the fold-activation in luciferase to pCMV-LacZ ratio compared to the reporter 
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alone. Error bars represent SD. n.s. = not significant; * p < 0.05; *** p < 0.001; n = 3. (Ref.: Figure data are 
included in manuscript in preparation/submission) 
Subcellular localization of the N-terminal Tfeb deletion clone 128-C and Δ129-237 did not 
change when over-expressed in C2C12 myoblasts and compared with the full-length FLAG-
tagged Tfeb isoform (Figure 24). Both clones and wild type Tfeb were localized to nucleus, 
cytosol and vesicular structures according to previous publications (Sardiello et al., 2009a; 
Settembre et al., 2012a). In contrast, Tfeb Δ238-400 and Tfeb Δ299-352, both lacking the 
bHLH domain (Figure 23 A), were localized to the cytoplasm and not found in the nucleus of 
C2C12 myoblasts (Figure 24).  
  
Figure 24: Subcellular localization of Tfeb deletion mutants in C2C12 myoblasts 
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Fluorescence images showing the subcellular localization of full length FLAG-Tfeb and indicated deletion mu-
tants of Tfeb in transfected C2C12 myoblasts, detected by immunofluorescence (24 h after transfection). Left 
panel shows immunostaining against FLAG tag and secondary antibody Alexa 488, right panel shows merged 
pictures with DAPI channel. Scale bars represent 20 µm. (Ref.: Figure data are included in manuscript in prepa-
ration/submission) 
In summary, Tfeb and HDAC5 interact with each other at their individual N-termini respec-
tively. HDAC5 inhibits Tfeb induced MuRF1 expression, most likely via its HDAC domain. 
Tfeb induced MuRF1 expression requires Tfebs’ bHLH DNA-binding domain.  
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3.7 Regulatory participation of PKD family  
Earlier studies showed that the stress-dependent protein-kinase D family (PKD) of ser-
ine/threonine kinases regulates the activity of ClassIIa HDACs. Therefore, it was investigated 
if PKD is involved in regulation of the here identified HDAC5/Tfeb/MuRF1 axis. 
First goal was to confirm physical interaction between HDAC5 and PKD family members. 
Both full length FLAG-HDAC5 and Myc-PKD1 showed strong interaction in Co-IP proce-
dure when co-expressed in HEK293 (Figure 25 A). In addition, full length FLAG-PKD2 in-
teracted with full length Myc-HDAC5 (Figure 25 B). In contrast, no interaction was detected 
between FLAG-HDAC5 and Myc-PKD3 (Figure 25 B).  
Secondly to confirm functional correlation between PKDs and the HDAC5/Tfeb axis was to 
over-express PKD cDNA expression plasmids in luciferase assays. Co-transfection of the 
M1P construct (size -543 bp) together with full length Tfeb showed increased M1P expres-
sion, which was inhibited by HDAC5 presence in HEK293 (Figure 25 C, third bar from left). 
In this setup wild type (WT), constitutive active (CA) or dominant negative (DN) isoforms of 
PKD1, 2 or 3 expressing constructs were used to investigate if PKDs can affect the repression 
of Tfeb by HDAC5. Both CA isoforms of PKD1 and PKD2 restored the HDAC5 mediated 
reduction of Tfeb induced MuRF1 expression (Figure 25 C). In contrast, the CA isoform of 
PKD3 showed no recovering effect in luciferase assay setup when co-transfected with 
HDAC5, Tfeb and the M1P (size -543 bp) constructs in HEK293 cells (Figure 25 C).  
3 Results 71 
 
Figure 25: Interaction of PKD family members with HDAC5 and their regulatory influence on Tfeb in-
duced MuRF1 expression 
(A and B) HEK293 cells were transfected with expression plasmids encoding full length wild type FLAG-
HDAC5 and constitutive active (ca) isoform of myc-PKD1 or FLAG-PKD2 or 3 constitutive active (ca) 
isoforms as indicated. Inputs of PKDs and HDAC5 proteins detected by immunoblot (IB) are shown in the top 
and middle panels. Inputs represent 10% of total lysates. Co-immunoprecipitated eluates representing PKD1 (A) 
or HDAC5 (B) protein are shown in the bottom panel. (C) HEK293 cells were transfected with expression plas-
mids encoding FLAG-Tfeb (wt) and HDAC5 (wt) and PKD1, 2 or 3 wild type (wt), constitutive active (ca) or 
dominant negative (dn) isoforms, as indicated, and the M1P reporter construct (size -543 bp). Values were nor-
malized to expression of pCMV-LacZ and calculated as the fold-activation in luciferase to β-Gal ratio compared 
to the reporter alone. Error bars represent SD. n.s. = not significant; * p < 0.05; ** p < 0.005; n = 3. (Ref.: Figure 
data are included in manuscript in preparation/submission) 
Previous studies of others and own findings of the Fielitz Lab showed that PKD1 gets activat-
ed by AngII and mediates translocation of HDAC5 out of the nucleus. To analyze the atro-
phying effect of AngII in skeletal muscle tissue in connection with PKD1, members of the 
Fielitz Lab used AngII perfusion via mini pumps in skeletal muscle specific PKD1 knock-out 
mice (PKD1 cKO) (Data are not included in this Thesis, but are included in manuscript in 
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preparation). The obtained results clearly showed that muscles (soleus and gastrocnemi-
us/plantaris) from PKD1 cKO animals were less atrophied than those from wild type animals. 
Knowing that PKD1 is sensitive to and gets activated by AngII, the role of Tfeb in AngII in-
duced atrophy was analyzed. To investigate if knock down of Tfeb inhibits AngII induced 
myotube atrophy, siRNA mediated knock-down of Tfeb in differentiated C2C12 myotubes 
and was performed. Differentiated myotubes (day 8) were transfected with siTfeb or scram-
bled control (100 nM each) for 24 h. Transfection with siTfeb resulted in a slight but signifi-
cant increase in myotube diameter compared to siScr control treated cells (Figure 26 C, black 
bars). AngII treatment (500 nM for 20 h) of identically treated myotubes showed reduced at-
rophy compared with siSCR control cells (Figure 26 A to C). To validate that Tfeb is in-
volved in AngII induced MuRF1 expression, ChIP analysis of chromatin from AngII and ve-
hicle treated C2C12 myoblasts were performed. Treatment of C2C12 myoblasts with 500 nM 
AngII for 3 h resulted in an enhanced binding of Tfeb towards E-box motifs of the MuRF1 
promoter compared to vehicle treated cells (Figure 26 D). These results showed that Tfeb is 
involved in AngII induced muscle atrophy by regulating expression of MuRF1. 
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Figure 26: siRNA knock-down of Tfeb prevents AngII induced atrophy in C2C12 myotubes 
(A, B and C) Differentiated C2C12 myotubes (8 days) were transfected with scrambled control siRNA (scr) or 
siRNA against Tfeb (siTfeb; 100 nM each), and treated with vehicle or Angiotensin II (AngII, 500 nM, for 20 h), 
as indicated. Pictures were taken and myotube width was analyzed from at least 100 myotubes per condition and 
3 Results 74 
at three random positions per myotube. Graphs show frequency histograms plotting the number (or percentage) 
of myotubes against the myotube diameter. Frequency histograms of scrRNA and Tfeb siRNA transfected 
C2C12 myotubes treated with vehicle or AngII are shown in A (siScr) and B (siTfeb); respectively. (C) Diagram 
shows statistical quantifications of measured mean diameters of 8 days differentiated C2C12 myotubes, treated 
and quantified as described above, with or without AngII treatment (AngII, 500 nM, for 20 h) after previous 24 h 
siRNA knockdown. Experiment has been repeated two times, showing the same trend. Graph shows tube diame-
ter distribution of one experiment. For analysis myotube widening of ten randomly taken pictures were quanti-
fied. Error bars represent SEM. * p < 0.05; ** p < 0.005; *** p < 0.001. (D) Chromatin immunoprecipitation 
(ChIP) assay in C2C12 myoblasts showing Tfeb binding to mouse MuRF1 promoter E-boxes. Cells were grown 
in normal 10 % FBS DME-Medium before angiotensin II (AngII) treatment (500 nM) or vehicle for 3 h. Chro-
matin was immunoprecipitated with antibodies against immunoglobulin G (IgG) or Tfeb. Primers flanking the E-
boxes on the MuRF1 promoter were used for amplifying DNA by real-time PCR. Calculation was carried out 
using delta- delta- cT method. (Ref.: Figure data are included in manuscript in preparation/submission) 
In summary, based on the data presented in this study and in-vivo data obtained from other lab 
members, a working model was postulated, which will be published in the near future and is 
shown in figure 27, at the end of the discussion part of this thesis. In an untreated condition, 
Tfeb can bind to the conserved E-box elements in the genomic MuRF1 promoter sequence. In 
this stage HDAC5 localizes to the nucleus, binds to and inhibits Tfeb mediated expression of 
MuRF1. When AngII is present, it binds to its receptor (AT1R) and activates PKD1 which 
than translocates to the nucleus, and binds to and phosphorylates HDAC5. Phosphorylation of 
HDAC5 leads to binding of the 14-3-3 chaperon protein mediating CRM1 dependent nuclear 
export of HDAC5. This relives inhibition of Tfeb which can now activate the expression of its 
target genes, such as MuRF1. Tfeb activates MuRF1 expression most likely via binding to the 
E-box motifs 1 and 3. In case of starvation the author assumes that Tfeb translocation in the 
nucleus gets enhanced, as findings of others showed for human TFEB. 
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4 Discussion 
Regulation of muscle function is complex and involves well orchestrated protein synthesis as 
well as fine tuned protein degradation. When protein degradation overvalues protein synthe-
sis, muscle atrophy can arise and critically influences sick individuals suffering from a variety 
of atrophy releasing diseases. Findings from the last two decades revealed that the E3 ubiqui-
tin ligase MuRF1 takes a crucial stand in the process control and mediation of muscle atro-
phy. Given that regulation of MuRF1 was not fully understood, the aim of this study was to 
identify new regulators of MuRF1 gene expression. This decision was based on the 
knowledge that MuRF1 is directly involved in and responsible for the degradation of structur-
al proteins in skeletal and in heart muscle tissue. (Clarke et al., 2007b; Cohen et al., 2009; 
Fielitz, van Rooij, et al., 2007; Kedar et al., 2004b)  
4.1 TFEB was identified as the strongest MuRF1 inducer    
The proximal regulatory promoter sequence of the human MuRF1 gene was screened for po-
tential candidates with a focus on activating transcription factors. A skeletal muscle derived 
cDNA expression library was screened, with a total sampling rate of more than 100,000 
clones. To obtain reliable read-outs, the screening procedure was repeated twice, using a 5 kb 
and a 1 kb genomic DNA fragment of the human MuRF1 promoter sequence, respectively. 
The findings received from first screening procedure were verified in the second screening 
that also reduced effects of variable DNA amounts resulting from DNA isolation during sib-
selection process.  
To find new transcriptional activators of MuRF1, the most potent and promising candidate 
was chosen. In this case it was the transcription factor EB (TFEB).  
Altogether, overall gene transcripts identified revealed a broad variety of genes potentially 
involved in regulation of MuRF1 expression. The majority of sequencing results revealed par-
tial cDNA fragments (23 out of 34). This result can be explained by the manufacturing proce-
dure of the applied cDNA library. The library contained cDNA fragments with an average 
size of ~1600 bp (purchased from Invitrogen).  
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4.2 TFEB regulates MuRF1 expression 
TFEB has been isolated separately six times in total during both screening processes, indicat-
ing to be a relevant candidate with high probability. The fact that two different forms of 
TFEB were isolated (a full length isoform as well as a partial unknown fragment) could be 
explained on the one hand by differential splicing of the inserted mRNA and on the other 
hand by truncation during the manufacturing process. Since sequencing did not reveal a start 
codon it is most likely that the obtained clone was truncated during the manufacturing pro-
cess. Anyway, the partial clone strongly induced the Hs_MuRF1-luc construct.  
Because the following analyses were planned in C2C12 mouse myoblasts, it was decided to 
use the mouse isoform of Tfeb. Since cloning from cDNA was without any result, it was de-
cide to buy the full length Tfeb mouse isoform A. The assembled Tfeb expression plasmid 
(FLAG-Tfeb, table 4) dose dependently induced the human MuRF1-luc construct. This result 
could be expected as protein sequences of human and mouse Tfeb are highly similar (93% 
total sequence identity, alignment shown in appendix figure 1).  
The fact that Tfeb over-expression resulted in endogenously increased MuRF1 mRNA levels 
and protein content in C2C12 myoblasts gave further reference towards an actual participation 
of Tfeb in the transcriptional regulation of MuRF1. 
4.3 Tfeb binding sites in the MuRF1-promoter are identified 
To indentify the specific region in the MuRF1 promoter at which Tfeb binds to the MuRF1 
promoter and increases its expression, first of all subsequent length reductions of the 
Hs_MuRF1-luc construct were performed.  
Tfeb binds to E-box motives (CANNTG (Carr & Sharp, 1990)) in the promoter regions of 
various genes (Sardiello et al., 2009b). It was shown by Moresi et al. that E-box motives are 
also present in the mouse MuRF1 promoter (Viviana Moresi et al., 2010b). Therefore a de-
tailed sequence analysis of the human MuRF1 promoter used in this study for luciferase assay 
analysis was performed, revealing multiple E-box sites in the human MuRF1-luciferase con-
struct located close to the transcriptional start site (TSS). To eliminate side effects of more 
distant E-box motives in the Hs_MuRF1-luc construct, length reduced variants of this con-
struct were used in luciferase assays. Results showed constant induction of the inserted 
MuRF1 promoter constructs, ranging down gradually from -5002 bp to -543 bp, when co-
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expressed with Tfeb expression plasmid. Further decline of the MuRF1 promoter construct 
reduced the Tfeb mediated induction gradually when reduced from -300 bp to -200 bp and 
subsequently to -100 bp upstream of the TSS. These results confirmed the existence of at least 
two potent binding sites close to the TSS of MuRF1. Findings from Ballebio et al. in 2011 
supported the presumption of a TSS near binding of Tfeb. Ballebio et al. used an over-
expression based ChIP-Seq method with a triple FLAG-tagged human TFEB in HeLa cells 
and revealed that a TSS near binding of TFEB is very important for the inducing effects of its 
target genes.  
Site directed E-box motive mutation confirmed their importance for Tfeb mediated MuRF1 
regulation. The first three E-box positions, out of the four positions identified in the Hs-
MuRF1-luc construct, are highly homologues throughout mammalian species. As shown be 
Moresi et al. another bHLH domain containing transcription factor, myogenin, binds to and 
regulates MuRF1 expression in mice upon denervation, most likely via the second and third 
E-box motive (Viviana Moresi et al., 2010b). Investigations of the E-box motives revealed 
that E-box position 1 and 3 seem to be more relevant for the Tfeb mediated induction than 
position 2 or 4. ChIP analysis performed in this study confirmed binding of endogenous and 
over-expressed Tfeb to the endogenous MuRF1 promoter sequence near the TSS, very likely 
via the amplified E-box motives. Using ChIP experiments, it was not possible to dissect Tfeb 
binding to different E-box sites, due to their very close proximity.  
Surprisingly, site directed mutagenesis of the fourth E-box motive resulted in an increase in 
Tfeb sensitivity, leading to the assumption of the presence of a regulatory element negatively 
influencing MuRF1 expression at this position, at least in the human promoter.  
Considering the data of Moresi et al. and own results it was reasoned that the E-box position 3 
in the MuRF1 promoter is used dually by myogenin and Tfeb. Whereas Tfeb individually uses 
E-box 1 and myogenin autonomously uses E-box 2, presumably. 
These three conserved E-box motives are located in between the FoxO transcription factor 
binding site (Waddell et al., 2008b) (Figure 2) and the MEF2 site close to the TSS of MuRF1 
(Baskin & Taegtmeyer, 2011b). Due to potential homo- and heterodimerization of Tfeb, it is 
most likely that multiple E-box binding sites are necessary for a maximum induction of 
MuRF1 expression. Different binding positions may have different effects on the formation of 
a transcriptional start complex, potentially with other transcription factors. Interestingly, pre-
liminary data point to a co-operational effect of MEF2A and Tfeb in the transcriptional regu-
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lation of MuRF1 (Appendix Figure 4). Further analyses are required to validate the functional 
relevance of these results. 
In summary, Tfeb induces MuRF1 expression via binding to conserved E-box motives in the 
MuRF1 promoter. 
4.4 Tfeb is required for starvation induced MuRF1 induction and 
its basal expression  
Using siRNA based loss-of-function approaches the connection between endogenous Tfeb 
and basal MuRF1 expression was investigated in C2C12 myoblasts. Reduction of Tfeb subse-
quently reduced endogenous MuRF1 mRNA and protein levels, indicating a participation of 
Tfeb in basal MuRF1 regulation. ChIP results support this assumption, due to proved binding 
of Tfeb to the endogenous MuRF1 promoter.  
Since Moresi et al. showed that bHLH transcription factor binding of myogenin to E-box mo-
tives in the MuRF1 promoter is relevant in denervation induced atrophy, this study investigat-
ed the role of the newly identified MuRF1 regulator and also bHLH transcription factor Tfeb 
in reference to AngII induced atrophy and starvation initiated C2C12 myoblast to myotube 
differentiation (Viviana Moresi et al., 2010b). Myogenin was shown to regulate MuRF1 ex-
pression in case of denervation induced atrophy, while it could not be proven to be relevant 
for MuRF1 induction during periods of fasting or starvation induced differentiation. Thus, it 
was tested if Tfeb might participate in MuRF1 regulation during starvation. Because MuRF1 
is strongly unregulated during muscle differentiation and myotube formation, it was analyzed 
if a lack in Tfeb content would affect MuRF1 expression during differentiation. And indeed 
knockdown of Tfeb inhibited the differentiation process. Supported by the findings of 
Settembre et al. and others who published starvation induced gene activation upon transloca-
tion of Tfeb into the nucleus, it was speculated if Tfeb binding to the MuRF1 promoter would 
increase in C2C12 myoblasts after serum starvation (Settembre et al., 2012b). Since ChIP 
experiments showed an enriched binding of endogenous Tfeb of over 20 fold to the proximal 
promoter sequence of MuRF1, the obtained results prove that Tfeb does play a central role in 
the regulation of MuRF1 in serum starvation induced muscle cell differentiation.  
Due to embryonic lethality of Tfeb knock-out mice and the fact that the targeted muscle spe-
cific knock-out mice could not be generated, it was not possible to investigate loss-of-function 
studies in-vivo. To investigate the function of Tfeb in-vivo it would be important to generate 
muscle specific gain- and loss-of-function animal models.  
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4.5 ClassIIa HDAC 4 and 5 repress Tfeb mediated MuRF1 
induction  
As introduced, the ClassIIa HDAC family members were shown to be potent negative regula-
tors of cardiac and skeletal muscle atrophy (Matthew J. Potthoff et al., 2007). Interaction of 
ClassIIa HDACs was shown for many other DNA-binding transcription factors, transcription-
al co-repressors, protein kinases as well as G-protein coupled receptors (Martin et al., 2007). 
Highly interesting for the studies investigations was the finding that class IIa HDACs interact 
with MEF2 transcription factor family members and by that negatively regulate MuRF1 ex-
pression. Based on these findings it was hypothesized that Tfeb induced MuRF1 expression 
could also be negatively regulated by class IIa HDACs. And indeed HDAC4 and 5 showed 
strongest inhibitory effects of the Tfeb induced Hs_MuRF1-luc construct induction. Support-
ed by Co-IP based interaction studies as well as co-localization analysis in C2C12 myoblasts 
it was shown that Tfeb mediated MuRF1 induction is strongly regulated by class IIa HDAC5 
and HDAC4, respectively. However, binding between HDAC5 and Tfeb was stronger com-
pared to HDAC4 and Tfeb. Previously it was shown by others that the two HDAC 4 and 5 
both regulate skeletal muscle atrophy and compensate each other (Viviana Moresi et al., 
2010b). No interaction or co-localization was found between TFEB and HDAC7 and 9, re-
spectively, suggesting that their inhibition of Tfeb mediated MuRF1 induction was indirect. 
Other interaction partners of the class IIa HDACs are: CAMTA2 (K Song Cell), a DNA-
anchoring transcriptional factor, which stimulates cardiac growth; and the NF-kB inhibitory 
transcriptional repressor IκBα, which is part of the NF-kB pathway, that also influences 
MuRF1 expression (Martin et al., 2007). Since plenty of the indentified HDAC interaction 
partners participate in the regulation of muscle maintenance and structural homeostasis as 
well as skeletal and heart muscle atrophy, the interaction analysis of the newly indentified 
MuRF1 regulator Tfeb and the ClassIIa HDACs became secondary aim of this study. 
In summary, the decision for the following detailed interactional and functional mapping be-
tween Tfeb and HDAC5 was based first on their physical interaction, second on their co-
localization, and third on functional assays with the Hs_MuRF1-luc construct.   
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4.6 HDAC5 interaction with full length Tfeb and is mediated by 
HDAC5s N-terminal amino acids 51-100  
The functional mapping of HDAC5 deletion mutants with full length Tfeb was performed 
using Co-IP and luciferase assays. Since HDAC5 mutant 1-664 showed no inhibitory effect in 
luciferase assays but stable interaction with full length Tfeb in Co-IP, it was assumed that the 
HDAC domain, which was missing in this mutant, does play a central role in the repression of 
the Tfeb mediated MuRF1 regulation. For future investigations, it would be of interest to see 
if Tfeb is also regulated via histone acetyl transferase (HAT) acetylation and possibly de-
acetylated by HDAC5 and its HDAC domain. Current literature does suggest that the balance 
of acetylation and de-acetylation has strong influences on protein stability and thereby affects 
muscle wasting (Alamdari et al., 2013). Acetylation or de-acetylation based regulation has not 
been reported for Tfeb so far.  
The interaction between full length Tfeb and HDAC5 was mediated by the N-terminal amino 
acids 51 to 100 of HDAC5. In addition to the decreasing interaction, the inhibitory effect ob-
served for full length HDAC5 on the Tfeb mediated MuRF1 induction declined, when com-
pared with the two deletion clones 51-C and 100-C of HDAC5. However, the deletion clone 
100-C showed a lower, but significant reduction of the Tfeb mediated MuRF1 induction. No 
interaction was detectable with full length Tfeb in Co-IP analysis. The author assumed that 
this effect could be indirect, possibly mediated via another transcription factor associated with 
Tfeb, e.g. MEF2 since its binding site in HDAC5 sequence is adjacent (Matthew J. Potthoff et 
al., 2007). It would be valuable to investigate this suggestion via a triple Co-IP approach and 
an expansion of the functional luciferase assay shown in the appendix with an additional in-
sertion of HDAC5. Further deletion of the following N-terminal amino acids of HDAC5 
(HDAC5 175-C) resulted in a complete loss of the negative regulatory influence of the Tfeb 
mediated MuRF1 induction. In addition, no interaction could be observed with full length 
Tfeb. Although the loading for the deletion mutants of HDAC5 of the represented experiment 
in figure 22 B is to a certain extent unequal, longer exposures of the eluate Western blots 
showed no interaction signal at all. Repeatedly performed experiments indicated identical 
results.   
In summary, the obtained results lead to the conclusion that the amino acids 51-100 of 
HDAC5 are critical for interaction with full length Tfeb and that the HDAC domain is neces-
sary for the negative regulation of the Tfeb mediated MuRF1 induction.   
4 Discussion 81 
4.7 Tfeb binds to HDAC5 via its N-terminal amino acids and 
requires its own bHLH domain to induce MuRF1 expression  
Since, in luciferase assays, the observed Tfeb mediated MuRF1 induction was stronger than 
every other transcription factor that has been linked to the regulation MuRF1 expression so far 
(Baskin & Taegtmeyer, 2011b; Cai et al., 2004b; Viviana Moresi et al., 2010b; Waddell et al., 
2008b), the protein regions and bHLH domain in Tfeb were analyzed for their involvement in 
MuRF1 promoter induction as well as inhibition via interaction with HDAC5. Deletion clone 
design was performed according to the formerly known structural data, extracted from OMIM 
and NCBI database. Presented results are in agreement with previous publications showing 
that the DNA binding of Tfeb was mediated by its bHLH domain. Deletion of this bHLH do-
main abolished induction of the Hs_MuRF1-luc construct and MuRF1 protein induction in 
C2C12 over-expression analysis, but did not reduce physical interaction with full length 
HDAC5. So it was concluded that the bHLH domain of Tfeb is relevant for DNA binding and 
subsequent induction of target genes, such as MuRF1, but not for HDAC5 interaction.  
In contrast, HDAC5 interaction could be connected to the N-terminal amino acids in Tfeb 
protein, shown by the complete loss of interaction when Tfeb deletion mutant 128-C was ap-
plied in Co-IP assay with full length HDAC5. This deletion mutant was missing the glycine-
rich region, which has not been linked to any regulatory or any other function so far. Looking 
at the distribution of the N-terminal deletion clone Tfeb 128-C in C2C12 myoblasts, the 
study’s results confirmed the findings of Roczniak-Ferguson et al. who reported that human 
TFEB lacking the first 30 amino acids was mainly localized in the nucleus (Roczniak-
Ferguson et al., 2012). As no NLS, NES or regulatory phosphorylation site has been pub-
lished for this region, this observation cannot be explained until know and needs to be further 
investigated in the future. Even though this deletion clone did mainly localize to the nucleus, 
it showed reduced ability in Hs_MuRF1-luc induction. Probably because of reduced dimerisa-
tion capacity, which needs to be tested in prospective analysis.  
For the internal Tfeb mutant missing amino acids 129-237, very similar Hs_MuRF1-luc in-
duction results were observed as for the N-terminal Tfeb deletion mutant 128-C. This internal 
section of Tfeb contained multiple phosphorylation sites, which were analyzed in human 
TFEB protein by other groups. It was shown that phosphorylation of these sites produced 
14-3-3 binding and maintained the complex inside the cytoplasm (Roczniak-Ferguson et al., 
2012; Settembre et al., 2012b). Therefore the results are in agreement with these observations, 
showing that this mutant is mainly localized in the nucleus. The author suggests the following 
4 Discussion 82 
explanation for the decline in Hs_MuRF1-luc induction: it could be reduced dimerisation abil-
ity due to deletion of the internal amino acids and a potential change in three-dimensional 
conformation. Tfeb deletion mutant Δ129-237 showed no sensitivity in luciferase assay anal-
ysis to full length HDAC5 inhibition. In addition, it can be assumed that HDAC5 binding 
with Tfeb is mostly mediated by the N-terminal amino acids of Tfeb and additionally by a 
partial internal region. To analyze this assumption in more detail, deletion mutants of Tfeb 
spanning smaller regions, e.g. 20-40 amino acids, need to be generated for future experiments. 
Additional Tfeb mutants would also be useful to characterize the dimerisation of Tfeb being 
necessary for MuRF1 induction, and could be used in Co-IP, ChIP and luciferase analysis to 
improve the understanding of MuRF1 regulation in more detail.  
As the internal deletion clone Tfeb Δ129-237 showed no significant changes in subcellular 
localization compared to the wild type Tfeb, it is most likely that the previously mentioned 
phosphorylated serine residues, described to be regulatory, are not as important for Tfeb regu-
lation in skeletal muscle cells as in HeLa cells, which were used by Settembre et al. and oth-
ers (Roczniak-Ferguson et al., 2012; Sardiello et al., 2009b; Settembre et al., 2012b).  
In summary, data show that the inhibitory influence of HDAC5 on Tfeb is mainly mediated 
via the N-terminal part of Tfeb and that the amino acids encoding for the bHLH domain of 
Tfeb are necessary for induction of MuRF1 expression. 
4.8 Upstream regulatory influences of PKD1 and 2 on HDAC5 
inhibit Tfeb induction of MuRF1 
Several publications indicated regulation of HDAC5 activity by PKD family members. More 
specifically, PKD1 was shown to phosphorylate HDAC5 (Huynh & McKinsey, 2006; Mat-
thews et al., 2006). And indeed, the experiments presented here showed a direct interaction of 
PKD1 and PKD2 but not PKD3 with HDAC5. In addition, it was shown by Harrison et al. 
that the PKD1-HDAC5 axis plays a role in cardiac stress signaling (Harrison et al., 2006). 
The authors drew a regulatory network from PKC-dependent PKD1 activation over HDAC5, 
which itself negatively regulates MEF2 transcription factors that activate genes necessary for 
cardiac hypertrophy growth. As introduced, MEF2 was reported to regulate MuRF1 expres-
sion as well (Baskin & Taegtmeyer, 2011b). On the basis of these findings the influence of 
the described PKD/HDAC axis on Tfeb was investigated using interaction analysis and lucif-
erase assays.  
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As shown in this study, the Tfeb mediated MuRF1 induction was strongly inhibited by 
HDAC5. But constitutive active isoforms of PKD1 or PKD2 reversed HDAC5 mediated in-
hibitory effects on Hs_MuRF1-luc construct indicating that PKD1 and 2 act in HDAC5 regu-
lation. This was supported by Co-IP based interaction analysis, which showed that PKD1 and 
PKD2 but not PKD3 interact with HDAC5. Interaction mapping analysis between PKD1 and 
HDAC5 were performed by other members of the Fielitz Lab and are included in the manu-
script in preparation. 
These findings can be explained by previous reports from Liu et al. and Xu et al., who 
showed that PKD1 mediates nuclear export of HDAC5 (Liu, Contreras, Shen, Randall, & 
Schneider, 2009; Xu et al., 2007). The analysis published by Xu et al. in 2007 showed that 
AngII rapidly increases HDAC5 phosphorylation and leads to its nuclear export in vascular 
smooth muscle cells. In this experiment AngII treatment induced MEF2 activity only moder-
ately (~2 fold), as measured by a 3xMEF2-luciferase reporter construct. In addition, also 
FoxO transcription factors are not responsible for the AngII induced MuRF1 expression and 
subsequently induced atrophy in skeletal muscles (T. Yoshida, Semprun-Prieto, Sukhanov, & 
Delafontaine, 2010b). The arising knowledge gap from these findings, concerning the AngII 
induced atrophy regulation working via MuRF1 induction, could not be explained by the 
MuRF1 regulating transcription factors identified so far.  
4.9 Tfeb knock-down in C2C12 myotubes blocks AngII induced 
atrophy  
Knowing that Tfeb is a very potent inducer of MuRF1 expression and that AngII increases 
MuRF1 expression, it was hypothesized that AngII induced atrophy was mediated by Tfeb. 
The experimental prove was performed using siRNA mediated Tfeb knock-down followed by 
AngII treatment in differentiated C2C12 myotubes. AngII induced atrophy of myotubes was 
inhibited in the absence of Tfeb.  
This can be explained by the reduction of basal MuRF1 protein content when Tfeb levels are 
reduced in advance and the missing induction of MuRF1 expression as a result from Tfeb de-
ficiency. In addition, ChIP analysis in C2C12 myoblasts showed an enhanced binding of Tfeb 
to the MuRF1 promoter, supporting the assumption of Tfeb being responsible for the tran-
scriptional activation of MuRF1 as a result of the atrophy stimulus AngII.  
In summary, Tfeb mediates AngII induced atrophy in C2C12 myotubes. These results fill the 
knowledge gap described by Yoshida et al. in 2010, who described FoxO transcription factors 
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to regulate the AngII mediated atrogin-1 induction and showed that MuRF1 is regulated inde-
pendently of FoxO by an unknown transcription factor.  
4.10 Potential cross-talk in lysosomal and proteasomal 
transcriptional gene regulation is mediated by Tfeb 
Since MuRF1 encodes for a muscle enriched RING-finger E3 ubiquitin ligase of the UPS, the 
finding that Tfeb induced MuRF1 expression was partially surprising. Namely because Tfeb 
was previously identified as a major regulator of lysosomal biogenesis and homeostasis, and 
has thus been linked to lysosomal and autophagosomal formation (Palmieri et al., 2011; 
Roczniak-Ferguson et al., 2012; Sardiello et al., 2009b; Settembre et al., 2012b). So far, the 
involvement of Tfeb to any other UPS related gene has not been described.   
Data presented in this study (Appendix Figure3) showed that Tfeb is expressed in different 
skeletal muscles and various parts of the heart, which is in agreement with data described pre-
viously by Kuiper et al. (Kuiper et al., 2004, Appendix Figure 3). In addition, parallel in-
creased expression of MuRF1 and Tfeb upon starvation could be detected in the gastrocnemi-
us muscle (GP) (Appendix Figure 2). This could be explained in part by own findings since 
Tfeb mediates MuRF1 regulation upon starvation, as well as findings of others showing a 
starvation induced translocation of Tfeb into the nucleus (Settembre et al., 2012b).  
Coming back to the lysosomal association of Tfeb and the newly discovered link to UPS gene 
regulation presented in this study, it is noteworthy that both processes, the lysosomal degrada-
tion and UPS mediated protein degradation, were shown to participate in skeletal muscle at-
rophy. It is of interest that the mTOR pathway, which has been shown to regulate TFEB and 
the classical autophagy pathway in mammalian cells, is not the major factor that controls au-
tophagy in muscle cells (Fanzani, Conraads, Penna, & Martinet, 2012b). Rapamycin mediated 
inhibition of the mTOR pathway only barely (~10 %) increases protein breakdown in differ-
entiated myotubes (Zhao et al., 2007b). This important publication connected lysosomal and 
proteasomal proteolysis to the IGF-1/AKT/FoxO3 pathway. Surprisingly, the authors did not 
show any MuRF1 regulation and addressed the complete proteasomal degradation to atrogin-
1. This is critical due to the previously introduced findings that atrogin-1 does not mediate the 
degradation of structural myofibrillar proteins, whereas MuRF1 does.  
Summing up, the newly identified MuRF1 regulator Tfeb could have similar connective func-
tions in lysosomal and UPS regulation as FoxO3. Tfeb was reported to be an mTOR target 
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and that it activates various lysosomal genes, if this particular lysosomal activation is im-
portant for muscle atrophy, it needs to be further studied in the future. As lysosomal gene reg-
ulation or lysosomal biogenesis and autophagy were not analyzed in this present study, it is 
difficult to discuss, which particular influences Tfeb might have had on these highly balanced 
mechanisms. Anyway, the received data constrain large evidence that Tfeb has to be consid-
ered as a key transcriptional regulator of the lysosomal as well as the atrophy marker gene 
MuRF1. 
4.11 Postulated pathway 
The data obtained by this study are summarized in a working model (Figure 27). In an un-
treated condition, Tfeb binds to the conserved E-box elements in the genomic MuRF1 pro-
moter sequence, but HDAC5 (maybe also HDAC4) inhibits MuRF1 expression. In presence 
of AngII, PKD1 (maybe PKD2) is activated via the angiotensin II type 1 receptor (AT1R) via 
PKC. Activated PKD1 now translocates to the nucleus, where it binds to and phosphorylates 
HDAC5, which than binds to the 14-3-3 chaperon protein that mediates nuclear export of 
HDAC5 (maybe also HDAC4) in a CRM-1 mediated mechanism. This relieves repression of 
Tfeb, which now activates MuRF1 gene expression. It can be assumed that Tfeb activates 
MuRF1 expression, most likely via binding to the E-box positions 1 and 3 in the MuRF1 
promoter.  
 
Figure 27: Schematic illustration of the postulated working model of AngII triggered MuRF1 induction 
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Left side shows the inactive state, where ClassIIa HDAC5 binds to Tfeb and blocks MuRF1 induction. In the 
right panel AngII binds to its plasma membrane bound receptor (AT1R), activates PKD1 via PKCε, which in 
turn initiates phosphorylation dependent 14-3-3 nuclear export of ClassIIa HDAC5 and enables Tfeb to activate 
MuRF1 expression.  
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5 Summary 
Skeletal muscle mass is permanently balanced as a result of fine tuned protein synthesis and 
degradation mechanisms. When overall protein synthesis exceeds degradation rates the result 
is muscle hypertrophy (increase in CSA of muscle fiber diameter). In contrast, skeletal muscle 
atrophy occurs when protein degradation exceeds protein synthesis, which happens in a varie-
ty of conditions, such as aging, starvation, cancer, cachexia or denervation. Degradation of 
muscle mass can sometimes be useful, e.g. as source for lipids, amino acids and glucose in 
case of critical malnutrition as well as several other physiological conditions. But a solid 
composition and thereby functional maintenance of muscles is necessary for healthy individu-
als as well as individuals suffering from atrophy releasing diseases as to retain their mobility 
and to preserve full heart functions. Since degradation of structural proteins in muscle tissue 
has been addressed mainly to the ubiquitin-proteasome-system, the regulation of the partici-
pating components needs to be understood in detail to develop constructive treatments and 
therapies for atrophy prevention. One of the key enzymes in skeletal and heart muscle atrophy 
is the E3 ubiquitin ligase MuRF1. Its expression levels and protein content was found to be 
elevated in almost every know atrophy model. MuRF1 is very critical for the muscles compo-
sition and thus their functional integrity, as it marks and initiates degradation of structural and 
contractile proteins via the UPS. Since MuRF1 plays a prominent role in muscle atrophy, its 
transcriptional regulation needs to be well understood to develop effective therapies for all the 
different atrophy models MuRF1 has been linked to. Several transcription factors (NF-κB, 
FoxO, myogenin and Mef2) have been identified to regulate MuRF1 at different ratios and in 
diverse atrophy models. Importantly, they do not explain all MuRF1 inducing events ob-
served. To fill some of the remaining knowledge gaps, the studies primary aim was to find 
new transcriptional regulators for MuRF1 and the second aim was to analyze potential in-
volvements of the obtained candidates in pathways affecting skeletal muscle atrophy.  
In summary, the major aim of this study was achieved. Tfeb was identified as a novel MuRF1 
regulator. In addition, evidence that Tfeb participates in AngII mediated atrophy were re-
ceived, at least in C2C12 myotubes. Furthermore it could be demonstrated that Tfeb is neces-
sary for C2C12 myoblasts to myotube differentiation. The significance of Tfeb for atrophy 
regulation became clear, since Tfeb is directly influenced by the MuRF1 regulating 
PKD/HDAC axis. Therefore, this study presents a new and parallel working mechanism regu-
lating MuRF1 expression.  
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6 Appendix  
 
Appendix Figure 1: Alignment of human and mouse TFEB protein sequences 
Graph shows protein sequence alignment of the longest mouse Tfeb isoform A and the longest human TFEB 
Isoform 2. Amino acids encoding annotated Glycine rich domain are marked in violet, basic helix-loop-helix 
(bHLH) domain in blue, leucine zipper domain in green and DUF3371 domain in red (DUF3371 domain has not 
been associated to any function so far). Annotated sequences refer to UniProt human TFEB Entry: P19484; 
mouse Tfeb Entry: Q6P203. Alignment was performed using NCBI  BLAST_P.  
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Appendix Figure 2: Starvation induced relative in-vivo expression of MuRF1 and Tfeb  
(A, B) Graphs show Real-Time expression analysis of mouse gastrocnemius (GP) and tibialis anterior (TA) 
muscle tissue. (A) MuRF1 and (B) Tfeb expression relative to Gapdh, of control mice (n=4) and 24 h starved 
mice (n=6). Error bars represent SD. Student’s t-test *p<.05; ***p<.001. 
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Appendix Figure 3: Relative expression of Tfeb in diverse muscle tissues  
 Real-Time analysis of Tfeb expression (relative to Gapdh) of (A) mouse skeletal muscle tissue. GP, gastrocnem-
ius; TA, tibialis anterior; EDL, extensor digitorum longus; SOL, soleus. And of (B) mouse heart muscle tissue to 
6. LA, left atrium; RA, right atrium; RV, right ventricle; LV, left ventricle; IVS, inter ventricular septum. Tissue 
was isolated from Bl6 WT mice, N=4.  
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Appendix Figure 4: Co-induction of M1P construct by Tfeb and MEF2A overexpression 
(A) HEK293 cells were transfected with expression plasmids encoding full length Tfeb and MEF2A together 
with the M1P reporter construct (size -543 bp), as indicated. Values were normalized to pCMV-LacZ transfec-
tion control vector expression and calculated as fold-activation in luciferase to β-Gal ratio compared to the re-
porter alone. Graph shows representative experiment in triplicates. Experiment has been repeated three times. 
Error bars represent SD. Students T-Test; ** p < 0.005. 
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